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SUMMARY 
 
Marine bacteria have considerable importance as sources of biologically active 
products. Marine microorganisms that live in cold regions have been largely 
underexplored, and may be endowed with interesting chemical repertoire. The 
microorganisms that thrive in these cold environments are referred to as 
psychrophiles or cold-adapted bacteria and are able to produce a large number of 
bioactive compounds, such as antimicrobial, anti-fouling and various 
pharmaceutically-relevant activities.  
In this contest, the aim of my PhD project was the research of new bioactive 
compounds of biotechnological interest from Polar marine bacteria. In particular, I 
focused my attention on three classes of molecules: 
I. Antimicrobial volatile organic compounds (VOCs); 
II. Anti-biofilm molecules; 
III. Cryoprotectant compounds. 
 
 Part I 
 
In order to explore the Pseudoalteromonas haloplanktis TAC125 (P.haloplanktis 
TAC125) chemical diversity as source of bioactive compounds, a suitable synthetic 
growth medium was developed, containing D-gluconate and L-glutamate as carbon, 
nitrogen and energy sources (GG medium). The definition of a synthetic medium is 
necessary for the scale up of P. haloplanktis TAC125 growth in automatic 
bioreactors. Moreover, a defined “minimum” medium could enhance the secondary 
metabolites production, and it surely makes their purification easier. Preliminary 
studies demonstrated that some Antarctic marine bacteria are able to produce 
volatile organic compounds (VOCs) that specifically inhibit the growth of Burkholderia 
cepacia complex (Bcc) strains. Amongst the tested Antarctic marine bacteria, 
P.haloplanktis TAC125 was further investigated. It is known that the P.haloplanktis 
TAC125 production of VOCs changes with growth medium composition. With the aim 
to identify the anti-Bcc VOCs, a suitable capture trap for volatile compounds was 
developed. A bioactive compound was identified, the methylamine, and its anti-Bcc 
activity was demonstrated by defining the Minimum Volatile Inhibitory Concentration 
(MVIC) on a panel of Bcc strains. 
 
 Part II 
 
Anti-biofilm molecules may have interesting biomedical applications in targeting 
adhesive properties of several insidious human pathogens. Previous results showed 
that the cell-free supernatant of P.haloplanktis TAC125 grown in static condition 
strongly inhibited bacterial adhesion. In particular, Staphylococcus epidermidis 
showed the highest susceptibility to the treatment. During this part of my PhD project 
the best conditions in which P.haloplanktis TAC125 produces the anti-biofilm 
compound/s were searched and a preliminary purification scheme was set up. In 
particular, the effect of growth mode, culture medium composition, growth phase and 
temperature was explored. The best production conditions were set as a benchmark 
for the scale-up of P.haloplanktis TAC125 anti-biofilm molecule/s in bioreactor. 
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 Part III 
 
Marine cold-adapted microorganisms may be also source of another interesting class 
of chemical compounds, known as cryoprotectors, as they are able to avoid ice 
crystal formation inside living cells. Freeze-thaw cycles are quite common in the cold 
regions, especially in Polar one. Cold-adapted microorganisms are accustomed to 
being frozen within their habitats. Such organisms are also expected to have evolved 
adaptations to survive repeated freezing and thawing, as these processes tend to 
damage living cells and attenuate cell viability. The cold-adapted bacterium Colwellia 
psychrerythraea strain 34H (C. psychrerythraea 34H), attracted particular attention 
because it was reported to physically interact with sea ice crystals and secrete 
cryoprotectants of polysaccharidic nature in culture medium as a survival strategy.  
During my project, it was demonstrated that C. psychrerythraea 34H cells are 
covered by a capsula: the determination of chemical composition of purified capsular 
material revealed a novel polysaccharidic structure. Indeed the capsula was made by 
a linear tetrasaccharide repeating unit containing two amino sugars and two uronic 
acid, one of which is amidated by a threonine. The presence of an amminoacidic 
decoration of the capsular polysaccharide is quite uncommon in marine bacteria, but 
more intriguing is the decoration with Thr residues, as glycosilated Thr residues are 
essential for the interaction of anti-freeze glycoproteins (AFGPs) with ice crystals. In 
line with this indirect observation, in vitro assays demonstrated that the C. 
psychrerythraea 34H capsular polysaccharide is endowed with ice re-crystallization 
inhibition activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
  
RIASSUNTO 
 
Premesse scientifiche: 
 
I microrganismi che colonizzano gli habitat marini sono produttori di un variegato 
numero di metaboliti secondari. Ad oggi è nota la struttura di almeno 17.000 
biomolecole di origine marina, ma la maggior parte di queste proviene da organismi 
che vivono in ambienti temperati o tropicali. Meno del 3% del totale, invece, proviene 
da organismi che vivono in ambienti estremi come gli ecosistemi polari, la cui 
biodiversità è ancora largamente inesplorata.  
Le regioni polari rappresentano, quindi, dei laboratori unici per lo studio dei 
meccanismi molecolari che gli organismi utilizzano per sopravvivere e adattarsi a 
condizioni estreme. Microrganismi che vivono in queste regioni sono chiamati 
psicrofili o adattati al freddo.  
Particolarmente interessante e oggetto di studio presso il laboratorio dove è stato 
svolto il mio progetto di dottorato è il batterio psicrofilo Gram-negativo 
Pseudoalteromonas haloplanktis TAC125 (P.haloplanktis TAC125) il cui genoma è 
stato completamente sequenziato e annotato nel 2005 da Medigue et al. Questo 
batterio, per il quale sono già disponibili sistemi genetici per l’espressione 
ricombinante di geni e per la creazione di mutanti genomici per inserzione e 
sostituzione, è in grado di crescere in un ampio intervallo di temperature e 
concentrazioni saline raggiungendo alte densità cellulari. Attualmente viene anche 
utilizzato come piattaforma tecnologica per la produzione di svariati tipi di proteine 
ricombinati tra cui alcuni anticorpi e proteine di interesse biomedico. Hanno catturato 
la nostra attenzione anche i microrganismi appartenenti al genere Colwellia, in modo 
particolare Colwellia psychrerythraea 34H (C.psychrerythraea 34H), che è stato 
isolato da sedimenti del mare Artico ed è considerato un organismo modello per lo 
studio degli adattamenti al freddo. Produce molecole di elevato interesse 
biotecnologico tra cui enzimi extracellulari e crioprotettori. 
Il mio progetto di dottorato si inserisce nell’ambito della ricerca di nuove molecole 
bioattive da microrganismi adattati al freddo. In particolare mi sono occupata di 
molecole volatili ad attività antimicrobica, molecole anti-biofilm e di composti ad 
attività crioprotettrice. 
 
Obiettivi: 
Il mio progetto di dottorato si è incentrato su tre aspetti principali: 
Parte I 
La ricerca di molecole volatili bioattive ad attività anti-microbica prodotte da P. 
haloplanktis TAC125 capaci di inibire la crescita di ceppi appartenenti al cosiddetto 
Burkholderia cepacia complex (Bcc).  
Parte II 
Ricercare molecole ad attività anti-biofilm prodotte da P.haloplanktis TAC125 che 
sono in grado di eradicare il biofilm di Staphilococcus epidermidis. Inoltre valutare 
come potenziali produttori di molecole anti-biofilm batteri marini Polari appartenenti 
ad altri generi. 
Parte III 
Studiare le molecole ad attività crioprotettrice prodotte da C.psychrerythraea 34H  
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Risultati e Discussione: 
 
Parte I 
 
Poiché la capacità dei microrganismi di produrre metaboliti bioattivi è spesso 
condizionata dalla composizione e natura del terreno di coltura, si è scelto di 
sviluppare un nuovo mezzo per P.haloplanktis TAC125. È stato quindi formulato il 
mezzo di coltura minimo e definito GG, il quale contiene D-gluconato ed L-
glutammato quali fonti di carbonio ed energia, scelti alla luce delle preferenze del 
microrganismo verso substrati di natura amminoacidica. Il GG non solo è ottimale per 
la crescita di P.haloplanktis TAC125 ma ha reso possibile anche lo sviluppo di 
processi di produzione in bioreattore automatizzato. Inoltre la scelta del terreno 
definito potrebbe portare ad un aumento della produzione dei metaboliti secondari e 
facilitarne la loro purificazione per la sua minore complessità rispetto ad un terreno 
ricco. 
È stato dimostrato che alcuni microrganismi marini Antartici, appartenenti al genere 
Pseudoalteromonas, sono capaci di produrre molecole volatili bioattive (Volatile 
Organic Compound/s, VOCs), che hanno la capacità di inibire la crescita di alcuni 
ceppi di Burkholderia cepacia complex (Bcc). I ceppi appartenenti al genere Bcc 
sono patogeni opportunistici responsabili delle infezioni polmonari in pazienti affetti 
da Fibrosi Cistica (FC) e sono particolarmente resistenti alla maggior parte degli 
antibiotici attualmente in commercio. Solitamente i pazienti affetti da FC sono trattati 
con combinazioni di due o più antibiotici, ma neppure questa è parsa fino ad oggi 
una strategia ottimale per abbattere la carica microbica. Da qui nasce la necessità di 
trovare altre molecole ad azione antimicrobica specifiche per le Bcc. 
È noto da letteratura che quando P.haloplanktis TAC125 cresce su un terreno 
agarizzato è in grado di produrre molecole volatili bioattive contro le Bcc, quindi il 
primo obiettivo è stato quello di verificare la produzione di VOCs attivi anche quando 
il batterio era cresciuto in terreno liquido. 
Per valutare la produzione di molecole volatili attive durante la crescita in liquido, è 
stato utilizzato un bioreattore automatizzato nel quale P.haloplanktis TAC125 è stato 
cresciuto in un convenzionale terreno complesso, dimostrando il rilascio di un 
numero elevato di VOCs attivi. Il passo successivo è stato lo sviluppo di un sistema 
efficiente per la cattura e l’accumulo delle molecole volatili prodotte dal 
microrganismo. Per realizzare ciò, è stato progettato una trappola per la cattura e 
l’accumulo dei VOCs che ha previsto la condensazione dei gas in uscita da un 
fermentatore inoculato con P.haloplanktis TAC125. Analisi di SPME-GC-MS hanno 
dimostrato che P.haloplanktis TAC125 è in grado di produrre un numero discreto di 
molecole volatili appartenenti a svariate classi chimiche. Data la complessità della 
“lista” dei VOCs prodotti dal microrganismo in terreno ricco, è stato utilizzato il 
terreno GG in precedenza ottimizzato come mezzo di crescita. È stato dimostrato 
che P.haloplanktis TAC125 non è in grado di inibire la crescita delle Bcc se cresciuto 
in GG, ciò conferma la dipendenza della produzione dei VOCs dalla composizione 
del terreno di coltura. La mancanza di produzione dei VOCs attivi in GG ci ha 
permesso di formulare un nuovo terreno di coltura il GG-metionina, ottenuto 
aggiungendo al GG la metionina. L’aggiunta dell’amminoacido come fonte di 
carbonio/azoto al terreno definito GG ha ripristinato la capacità inibente da parte di 
P.haloplanktis TAC125 sulle Bcc. Grazie alla disponibilità del sistema di cattura sono 
state identificate le molecole volatili, prodotte in questa condizione attraverso analisi 
di SPME-GC-MS, e tra le molecole identificate abbiamo focalizzato la nostra 
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attenzione sulla metilammina a causa della sua bassa tossicità per l’uomo e la facilità 
di manipolazione in laboratorio. Per valutare la tossicità della metilammina sulle Bcc 
è stato messo a punto un sistema per la valutazione della Minima Concentrazione 
Inibente della molecola Volatile (MVIC). Ed è stata valutata la MVIC della 
metilammina su un pannello più ampio di Bcc. 
 
Parte II 
 
Il biofilm può essere considerato come una comunità multicellulare, costituita sia da 
procarioti che da eucarioti, immersa in una matrice che in parte è sintetizzata dalle 
cellule stesse. I biofilm batterici sono responsabili, nell’uomo, della maggior parte 
delle infezioni persistenti. Infatti, i biofilm possono ostruire cateteri e causano 
infezioni negli impianti ortopedici. 
La causa più frequente d’infezione di protesi è a carico degli Staphilococchi perché 
sono microrganismi già presenti sulla pelle umana e nelle mucose. La virulenza a 
carico degli Staphilococchi è dovuta alla capacità di questi di formare biofilm su 
superfici sia biotiche sia abiotiche. Tra tutti gli staphilococchi, Staphylococcus 
epidermidis (S.epidermidis) è particolarmente difficile da eradicare ed è coinvolto 
nella maggior parte delle infezioni croniche a carico del biofilm. Nasce quindi la 
necessità di studiare nuove molecole ad attività anti-biofilm mirate a non intaccare la 
vitalità cellulare per evitare la comparsa di mutanti resistenti.  
La ricerca di nuove molecole ad attività anti-biofilm è il presupposto nel quale si 
inserisce la seconda parte del mio lavoro di tesi. È già stato dimostrato che il 
surnatante di P.haloplanktis TAC125 cresciuto in statico è in grado di inibire la 
formazione del biofilm di S.epidermidis.  
Al fine di rendere possibile la purificazione della/e molecole bioattive, è stato 
essenziale definire le condizioni di processo ottimali per la sua massima produzione. 
In particolare, sono stati oggetto di valutazione ed ottimizzazione i seguenti  
parametri di processo: la temperatura di crescita, la natura chimica del supporto; le 
modalità di crescita stessa; l’effetto della composizione del terreno di coltura.  
Le informazioni così ottenute sono state poi direttamente utilizzate nello sviluppo di 
un processo su larga scale in un bioreattore automatizzato da tre litri. La produzione 
in fermentatore permette non solo di ottenere grandi quantità di surnatante, ma 
anche di recuperare le cellule cresciute in biofilm per studi di tipo fisiologico. Per la 
crescita di P.haloplanktis TAC125 in fermentatore in biofilm, sono stati 
appositamente studiati supporti di polistirene, che hanno permesso la formazione del 
biofilm all’interfaccia tra aria e liquido. Questa strategia ha permesso una produzione 
su larga scala della molecola d’interesse e di capire la diversa fisiologia delle cellule 
cresciute in biofilm o in planctonico. In particolare per gli studi fisiologici, è stato 
analizzato il lipopolisaccaride. 
Poi si è passati ad uno screening preliminare di microrganismi appartenenti al genere 
Pseudoalteromonas, Psychrobacter, e Psychromonas allo scopo di valutare la loro 
eventuale capacità di produzione di molecole anti biofilm su altri patogeni.  
In particolare sono state eseguite delle crescite in sessile e in plantonico di una 
piccola collezione di batteri psicrofili polari. I surnatanti di queste crescite, sono stati 
utilizzati per valutare l’inibizione della formazione di biofilm su differenti specie di 
patogeni tra cui S.epidermidis, P. aeruginosa PAO1 e tre strains appartenenti al 
genere Staphylococcus aureus (S. aureus). 
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Soltanto alcuni dei ceppi hanno mostrato avere attività, in modo particolare 
Psycrobacter sp. TAD1, P.haloplanktis TAE79, P.haloplanktis TAE80, Psychrobacter 
articus 273-4 e Psycromonas artica, sono capaci di produrre molecole anti-biofilm.  
Sui surnatanti di queste crescite sono state fatte delle preliminari caratterizzazioni 
chimiche e si è visto che ciascuno di loro può produrre molecole di natura differente 
a seconda della modalità di crescita (plantonico o sessile). Ancora, ciascuno di questi 
ceppi può produrre molecole attive di differente natura chimica a seconda del ceppo 
bersaglio su cui va ad agire. È stata inoltre fatta una caratterizzazione chimico-fisica 
che ha confermato la differente natura di ciascuna delle molecole anti-biofilm. 
 
Parte III 
 
I batteri freddo adattati sono capaci di produrre un’altra classe di molecole 
interessanti a livello industriale: i crioprotettori. Questa classe di molecole è 
essenziale per la sopravvivenza in ambienti estremi in quanto non permette la 
formazione di ghiaccio nella cellula evitandone il congelamento. I crioprotettori di 
origine naturale hanno svariate applicazioni biotecnologiche che vanno dall’industria 
alimentare a quella medica come la crioconservazione degli embrioni.  
Tra i vari batteri psicrofili notevole interesse lo ha suscitato Colwellia psychrerythraea 
34H (C.psychrerythraea 34H) della quale è stato sequenziato e annotato il genoma 
nel 2005. 
C.psychrerythraea 34H è in grado di produrre molecole ad attività crioprotettrice 
come strategia di sopravvivenza per l’adattamento al freddo. In questo scenario, 
s’inserisce l’ultima parte del mio progetto di dottorato: la ricerca di molecole ad 
attività crioprotettrice da batteri adattati al freddo. 
Sono state messe a punto le condizioni di crescita per il batterio C.psychrerythraea 
34H con il fine di ottenere elevate biomasse per la successiva caratterizzazione 
chimica delle molecole di interesse.  
Le analisi chimiche hanno mostrato che C.psychrerythraea 34H è dotata di una 
capsula di natura polisaccaridica che mostra una struttura del tutto inusuale tra 
quelle note. In particolare, si presenta come un polimero la cui unità ripetitiva è 
costituita da un tetrasaccaride contenente due ammino zuccheri e due acidi uronici di 
cui uno ha legato un residuo di treonina. La decorazione amminoacidica su uno 
zucchero è una struttura del tutto nuova e inusuale tra i batteri. È noto in letteratura 
che le proteine anti-freeze di alcuni organismi superiori possono essere 
caratterizzate dalla presenza di treonina che ne permettono l’interazione con il 
ghiaccio.  
Sulla capsula di C.psychrerythraea 34H sono stati effettuati saggi di 
ricristallizzazione con il ghiaccio i quali hanno mostrato che la capsula di è capace di 
interferire con la cristallizazione del ghiaccio stesso. 
 
Risultati conseguiti: 
 
È stato ottimizzato un terreno definito per P.haloplanktis TAC125: il GG.  
L’ottimizzazione del GG ha permesso di studiare i metaboliti secondari prodotti da 
P.haloplanktis TAC125. Il GG ci ha consentito non solo di fare delle crescite in 
fermentatore, ma anche di facilitare la purificazione dei metaboliti secondari prodotti 
da P.haloplanktis TAC125. 
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È stata trovata la prima molecola volatile ad attività antimicrobica specifica contro le 
Bcc da P.haloplanktis TAC125: la metilammina. Di tale molecola è stata valutata la 
minima concentrazione inibente sulle Bcc  
Sono state ottimizzate le condizioni di produzione della molecola anti-biofilm da 
P.haloplanktis TAC125 contro S.epidermidis. In particolare sono state esplorati vari 
terreni di crescita, temperature e supporti.  
P.haloplanktis TAC125 produce biofilm su supporti di polistirene, la produzione della 
molecola anti-biofilm è dipendente dal terreno di coltura, al contrario non dipende 
dalla temperatura. Inoltre è stato definito un sistema per la crescita in biofilm in 
fermentatore che ha permesso da un lato di ottenere grosse quantità di campione 
per la purificazione, dall’altro di ottenere cellule cresciute in biofilm da utilizzare per 
studi fisiologici.  
È stato dimostrato che C.psychrerythraea 34H è un microrganismo capace di 
produrre una capsula. La struttura è di natura polisaccaridica con decorazioni 
amminoacidiche. Tale molecola, la cui struttura è del tutto nuova, presenta attività 
crioprotettrice poiché è in grado di inibire il processo di cristallizazione del ghiaccio. 
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1. Marine Biotechnologies 
 
More than 70% of the Earth’s surface is covered by the ocean which contains a vast 
collection of diverse microbial communities, all interacting with each other and with 
the environment around them. In fact, it is estimated that the ocean contains the 
highest percentage of prokaryotic cells on Earth, with a reported 3.67 × 1030 cells [1]. 
It is believed that specific physiochemical properties of the marine environment, such 
as pressure, temperature, pH, osmolarity, and uncommon functional groups (such as 
isonitrile, dichloroimine, isocyanate, and halogenated functional groups) may result in 
the production of bioactive substances with different properties from those found in 
terrestrial habitats [2]. 
Therefore, the marine habitat continues to be a source of unique natural products 
used for pharmaceutical and biotechnological applications [3]. In fact, the Roman 
philosopher Plinius first described the use of marine natural organisms such as 
sponges in medicinal applications, such as for the treatment of wounds, sunstroke 
and infections, around 2000 years ago [4]. More than 20,000 structurally diverse 
marine natural products have been isolated form marine organisms [5].  
Major pharmaceutical companies have been exploring marine compounds for several 
decades, but their investments and interest ceased when synthetic combinatorial 
compound libraries emerged since they were simpler and more cost-efficient for the 
high-throughput screening. However, the combinatorial chemistry approach failed to 
produce enough new drug entities, and in the recent years, there has been an 
emergence of small biotechnology companies marketing marine-based drugs [6]. 
Examples of approved drugs and potential therapeutic compounds derived from 
marine sources are given in Table 1. 
 
Therapeutic class Compound Chemical 
classification 
Source organism 
Cancer Aplidine, plitidepsin 
(Aplidin®) 
Depsipeptide 
Tunicate Aplidium 
alpicans 
 Brentuximab 
vedotin (Adcetris™) 
Antibody-drug 
conjugate 
Monomethyl auristatin E, 
synthetic, based on 
dolastatin 10, sea 
hare Dollabella 
auricularia/cyanobacteria 
 Cytarabine, Ara-C 
(Cytosar-U, 
Depocyt) 
Pyrimidine 
nucleoside 
Sponge Cryptotheca 
crypta 
 Elisidepsin 
(Irvalec®) 
Depsipeptide Synthetic, based on 
kahalalide F, mollusc 
Elysia rufescens 
 Eribulin mesylate 
(Halaven®) 
Macrolide Synthetic, based on 
halichondrin B, sponge 
Halichondria 
 Trabectedin 
(Yondelis®) 
Alkaloid Tunicate Ecteinascidia 
turbinata 
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Therapeutic class Compound Chemical 
classification 
Source organism 
 Jorumycin 
(Zalypsis®) 
Alkaloid Mollusc Jorunna funebris 
Schizophrenia DMXBA (GTS-21) 
anabaseine 
derivative 
Alkaloid Synthetic, based on 
anabaseine, marine 
worm Paranemertes 
peregrine 
Pain Ziconotide (Prialt®) Peptide Cone snail Conus 
magus 
 Tetrodotoxin 
(Tectin®) 
Alkaloid Pufferfish 
Tetraodontidae 
 
Table 1: Approved drugs and potential therapeutic compounds derived from marine 
sources. Source: http://marinepharmacology.midwestern.edu/clinPipeline.htm 
 
Moreover, the importance of marine organisms as source of new natural products 
promotes the launch of large scale marine biotechnology projects, in the European 
Union. Horizon 2020 program is strongly supporting the investments in marine 
research and innovation started during the previous 7th Framework Program, in 
which several marine biotechnology projects based on drug discovery were founded: 
MAREX – Exploring marine resources for bioactive compounds: from discovery to 
sustainable production and industrial applications (2010–2014), BAMMBO – 
Sustainable production of biologically active molecules of marine based origin (2011–
2014), PharmaSea – Increasing value and flow in the marine biodiscovery pipeline 
(2012–2016), SeaBioTech – From sea-bed to test-bed: harvesting the potential of 
marine microbes for industrial biotechnology (2012–2016).  
Amongst marine organisms that are excellent sources for many industrial products, 
marine microorganisms continue to be a major focus of many natural product 
research efforts, with a 10% increase in the number of compounds reported from 
2011 to 2012 [7]. 
Marine bacteria include archaea and eubacteria: archaea is an interesting group of 
bacteria since many of them are extremophiles, organisms that live in extreme 
conditions, e.g., deep sea, thermal vents, low temperature, or chemically challenging 
environment (salinity, pH, heavy metals). Marine eubacteria consist of Gram-positive 
actinomycetes and bacilli, Gram-negative α-proteobacteria and γ-proteobacteria and 
several anoxygenic anaerobes [8]. Marine bacteria as well as marine fungi, 
cyanobacteria and some microalgae are living as symbionts in sediment, sponges or 
other invertebrates [9]. Several marine bacteria can be grown in laboratory cultures 
and thus only small amounts of sample are required for cultivation, or metagenomic 
approaches can be used to build libraries [10]. 
Sometimes, marine bacteria live in association with other organisms, which lack 
obvious structural defense mechanisms, and thus rely on chemical defense by 
production of bioactive secondary metabolites, either by themselves or by associated 
microflora, to survive in their extreme habitat. In the last decades, the number of 
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reported secondary metabolites from marine bacteria has strongly increased, thus 
reflecting the growing attention by research groups from academia and industry [5]. 
Marine bacteria produce several classes of compounds. Around 100 novel 
compounds (e.g., polyketides, alkaloids, fatty acids, peptides and terpenes) are 
isolated from marine bacteria per year [8]. Bacterial metabolites are probably the 
most promising source for novel antibacterial, [11], is a potential antiobiotic against 
MRSA (Methicillin-Resistant Staphylococcus aureus ) and vancomycin-resistant 
enterococci.  
 
2. Polar bacteria as source of bioactive natural products 
 
We know that the marine habitat is extremely complex and contains a vast diversity 
of life forms, considering that the water column of oceans contains about 106 
bacterial cells per milliliter [12].  
The majority of marine organisms studied have originated from tropical and 
temperate waters. As a consequence, fewer than 3% of reported marine natural 
products originate from organisms collected in Polar habitats, despite the fact that 
one entire continent and a significant portion of global shallow-water habitat are 
found at polar latitudes. 
Cold-water microbial biodiversity is largely unexplored but recent efforts to 
characterize Polar marine microbial communities have demonstrated them to be rich 
and often uncharacterized [13]. The microorganisms that thrive in these cold 
environments are referred to as psychrophiles or cold-adapted. Cold-adapted 
bacteria are microorganisms able to survive in habitats where the average 
temperatures are permanently or transiently below 15 °C (temperature: -2-15°C). 
These low temperature conditions impose several challanges to living organisms, 
especially the unicellular ones, such as the exponential decrease of biochemical 
reaction rates, change in medium viscosity which makes reaction rate more slowly, 
changes in membrane fluidity and protein conformation, nutrient availability, ability to 
reproduce and protection against freezing condition [14, 15]. Even in this condition, 
cold-tolerant organisms manage to survive due to modification made to cytoplasmic 
membrane, supramolecular assembly processes, secondary structure of nucleic acid 
and to adaptations in either extra- or intracellular enzymes [14]. 
Most cellular adaptations to low temperatures and the underlying molecular 
mechanisms are not fully understood. This includes studies on the regulation of 
membrane fluidity, the maintenance of protein synthesis and the production of cold-
acclimation proteins, and the mechanisms of freeze tolerance [16]. In psychrophilic 
bacteria the presence of cryoprotective molecules [17], antifreeze proteins [18] and 
exopolymers [19] can buffer these organisms against the damaging effects of 
intracellular ice formation. Enzymatic structural adaptations, [20] including a 
reduction in protein residues displaying ion-pairing, hydrogen bonding and even  -
stacking aromatic interactions, [21] have enabled these organisms to maintain 
metabolic rates commensurate with their mesophilic congeners [22]. 
Protected against ice formation and enzymatically adapted to function most efficiently 
at low temperature, psychrophiles are subject to switch metabolic energy and other 
secondary metabolic resources to chemical defence as are mesophiles. 
Following this raising of interest concerning cold-adapted marine bacteria, in the very 
recent years few papers reported their ability to produce a large number of bioactive 
compounds. A preliminary characterization of these molecules demonstrate that are 
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endowed with antimicrobial, anti-fouling and various pharmaceutically-relevant 
activities [23, 24].  
Amongst the Polar marine bacteria that are able to produce bioactive products, 
Pseudoalteromonas haloplanktis TAC125 (P.haloplanktis TAC125) and Colwellia 
psychrerythraea 34H (C.psychrerythraea 34H) have been deeply investigated. 
 
3. The cold-adapted model microorganisms  
 
3.1 Pseudoalteromonas haloplanktis TAC125 
 
P.haloplanktis TAC125 is a Gram-negative bacterium isolated from an Antarctic 
coastal seawater sample collected in the vicinity of the French Antarctic station 
Dumont D’Urville, Terre Adélie (66°40’ S; 140° 01’ E). It can be classified as a 
eurypsychrophile and was the first Antarctic Gram-negative bacterium of which the 
genome was fully sequenced and carefully annotated. Several exceptional genomic 
and metabolic features were derived from the genome sequence of this bacterium, 
showing adaptation to periodic situations of nutrient abundance. P.haloplanktis 
TAC125 is one of the most intensively investigated, as the bacterium is one of the 
fastest growing psychrophiles characterized so far and it is able to grow in a quite 
wide temperature range (0-25°C) [25]. Furthermore, P.haloplanktis TAC125 is 
considered to be one of the model organisms of cold-adapted bacteria and it is the 
first Antarctic marine bacterium for which a genome-scale metabolic reconstruction is 
also available [26]. The determination of P.haloplanktis TAC125 genome revealed 
that the bacterial genome is characterized by a quite high number of rRNA and tRNA 
genes (106, sometimes organized in long runs of repeated sequences), which may 
account for its relevant capacity for translation and fast growth performances at low 
temperatures. Fast growth rates, combined with the ability of P.haloplanktis TAC125 
to reach very high cell densities even under laboratory growth conditions and to be 
easily transformed by intergeneric conjugation [27], made this bacterium an attractive 
host for the development of an efficient gene expression system at low temperatures 
[28]. Indeed P.haloplanktis TAC125 has been suggested as an alternative host for 
the soluble overproduction of heterologous proteins [29, 30]. In view of its application 
for industrial purposes, laboratory-scale fermentation processes have been 
developed, demonstrating the feasibility of P.haloplanktis TAC125 growth in batch 
[31], in a C-limited chemostat cultivation [32], and in fed-batch fermentations [29]. 
The efficiency of cold-adapted expression systems was also validated by the 
successful production of difficult proteins and biopharmaceuticals [30, 32, 33, 34]. 
The increasing interest in P.haloplanktis TAC125 has led to the accumulation of 
different data types for this bacterium in the last few years, including its complete 
genome sequence [25], its proteome [35, 36] and detailed growth phenotypes [29]. 
Thus, it is now possible to integrate such different data sources and perform a 
system-level investigation of P.haloplanktis TAC125 metabolism. Furthermore, 
bacteria belonging to the genus Pseudoalteromonas are known to possess an 
inhibitory activity against human pathogens belonging to the Burkholdeia cepacia 
complex (Bcc) and to be able to produce anti-biofilm molecules [24, 37], thus 
revealing the interesting biotechnological potential and metabolic biodiversity of this 
microorganism.  
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3.2 Colwellia psychrerythraea 34H 
 
Among the cold-adapted bacteria, the genus Colwellia is strictly psychrophilic. In 
particular, C.psychrerythraea 34H isolated from Arctic marine sediments represents 
the type species of the genus Colwellia [38]. C.psychrerythraea 34H has been 
considered as a model for the study of life in permanently cold environments, reveals 
capabilities important to carbon and nutrient cycling, bioremediation, production of 
secondary metabolites, and cold adapted enzymes. It grows reliably in heterotrophic 
media over a temperature range of approximately 1°C to 10°C, with cardinal growth 
temperatures ranking among the lowest for all characterized bacteria. From a 
genome-level perspective, adaptations potentially beneficial to life in cold 
environments can be seen in several broad categories. The determination of C. 
psychrerythraea 34H genome revealed that several of the adaptive strategies appear 
to increase fitness by effectively overcoming multiple obstacles at low temperature, 
including temperature-dependent barriers to carbon and nitrogen uptake. These 
strategies are reflected in expansions of gene families related to cell membrane 
synthesis, a capacity for uptake or synthesis of compounds that in part may confer 
cryotolerance, including PHAs (which may also aid in pressure adaptation), 
cyanophycin-like compounds, and glycine betaine, as well as the capacity to produce 
large quantities of extracellular enzymes [39]. Majority of organic matter in marine 
environments is composed of high-molecular-weight compounds that are largely 
unavailable for direct uptake by heterotrophic bacteria, the hydrolytic activity of 
extracellular enzymes plays a crucial role in bacterial acquisition of dissolved organic 
matter. The role of this activity is thought to be particularly important in low-
temperature environments, in which bacterial activity is believed to require higher 
levels of dissolved organic matter than the bacterial activity in warmer environments 
requires. C. psychrerythraea 34H also produces extracellular polysaccharides [40] 
Usually extracellular polysaccharides can serve as cryoprotectants and extracellular 
enzyme production may represent another mechanism for overcoming threshold 
requirements for dissolved organic carbon in cold environments. The production of 
EPS from C. psychrerythraea strain 34H was tested in extreme life conditions (up to -
14°C, 200 atm and 100% of salinity); the results obtained from Marx et al. in 2009 
[40] showed a dramatic increase of EPS production when the life conditions get 
worse. C. psychrerythraea 34H was selected as a model organism for genomic 
studies of bacterial cold adaptation.  
 
4. Aims of the study 
 
In this contest, the aim of my PhD project is the identification and characterization of 
new bioactive molecule/s from marine microorganisms to be implemented in 
industrial processes. There are three groups of bioactive molecules that have 
attracted our attention: volatile organic compounds VOCs, anti-biofilm molecules and 
cryoprotectant compounds. 
For the sake of clarity, the results of my project will be described in three different 
sections: 
i. Research of bioactive volatile organic compound/s against Burkholderia 
cepacia complex. 
ii. Identification of anti-biofilm molecules against Staphilococcus epidermidis. 
iii. Study of “cryoprotectant” molecules for biotechnological application. 
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I 
 
 
Antimicrobial volatile organic compounds 
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Topic I: Antimicrobial volatile organic compounds (VOCs) from Antarctic 
microorganism against Bcc complex 
 
Inappropriate or unnecessary antibiotic uses (either in human or in veterinary 
applications) appear to be the key contributors to the emergence of antibiotic 
resistance. The increasing threat of multidrug resistant pathogens and the continuing 
evolution of resistance make paramount the need to develop new antimicrobial 
therapies [41]. 
In this contest, natural products play an important role in drug discovery, as many 
approved therapeutics as well as drug candidates are derived from natural sources. 
Particular interest for biotechnological applications is the inhibitory effects of 
microbial volatiles against the growth of the others microorganisms. 
Microorganisms usually produce a wide range of compounds, many of which are 
volatile. The most of microorganisms produce unique reproducible volatile organic 
compounds profile (VOCs) under specific conditions (e.g. medium composition). 
Generally VOCs belong to several chemical classes (aldehydes, alcohols, esters, 
lactones, terpenes and sulphur compounds) and are characterized by low molecular 
weight [42, 43]. 
Some Antarctic marine bacteria are able to produce volatile organic compounds 
(VOCs), probably in response to environmental pressure, that specifically inhibit the 
growth of Burkholderia cepacia complex (Bcc) strains [44]. 
Most Bcc species are also opportunistic human pathogens, being particularly 
problematic for immuno-compromised individuals (including Cystic Fibrosis patients) 
since they are often multidrug resistant. There is therefore a need for novel and 
effective antimicrobial agents against Bcc strains. 
P. haloplanktis TAC125 is able to produce antimicrobial volatile compounds able to 
inhibit the growth of Bcc complex strains.  
In particular, in this section of my PhD dissertation you will find two papers: 
 In the first paper, the optimization of a defined medium GG (D-gluconate and 
L-glutamate) is described. In GG broth, P. haloplanktis TAC125 is capable to 
growth with a good biomass yield and quite fast speciﬁc growth rate even at 
sub-zero temperatures and it will be fundamental in the definition of survival 
strategies, used by P. haloplanktis TAC125, to face sub-zero temperature 
conditions. Besides use of P. haloplanktis TAC125 as cell factory for 
recombinant protein production, the bacterium does share with many other 
Pseudoalteromonales the striking ability to produce bioactive secondary 
metabolites of biotechnological relevance, such as anti-biofilm molecules [24] 
and volatile organic compounds (VOCs), active against a group of human 
opportunistic pathogen called Burkholderia cepacia complex (Bcc) [37]. In 
order to explore the P. haloplanktis TAC125 potentiality as source of bioactive 
compounds and non-conventional systems for the recombinant protein 
production, it is necessary to develop a synthetic medium for growth at low 
temperature. The definition of a medium is the requirement for scale up of the 
P. haloplanktis TAC125 growth in automatic bioreactors. Moreover, a defined 
“minimum” medium could enhances the secondary metabolites production and 
it surely makes easier their purification from extracellular medium. 
 
 In the second paper, the strategy set up for the capture and identification of P. 
haloplanktis TAC125 VOCs is described. Confirming the tight dependence of 
their production on the specific growth medium composition, results reported 
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in the paper demonstrate that the bacterium grown in GG medium is not able 
to produce any VOCs active against Bcc strains. Starting from this concept, a 
new medium was developed adding methionine to GG. When grown in GG 
supplemented with L-methionine, P. haloplanktis TAC125 recovered largely its 
inhibitory potential. Further, the paper describes the set up of a suitable VOCs 
capture trap and accumulation of condensed VOCs allowed their analysis by 
SPME-GC-MS. We reported for the first time the identification of methylamine 
as one of the VOCs responsible to inhibition of Bcc growth and the minimum 
Inhibitory methylamine concentration was established. 
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Abstract 
 
The Antarctic bacterium Pseudoalteromonas haloplanktis TAC125 is a model 
organisms of cold-adapted bacteria and it has a great biotechnological potential as 
non-conventional systems for the recombinant protein production and as source of 
bioactive compounds. In this paper, in order to deeply explore P.haloplanktis TAC125 
biotechnological potential, a synthetic medium for bacterium growth at very low 
temperature was developed. The new medium containing D-gluconate and L-
glutamate allowed P.haloplanktis TAC125 growth in a range of temperatures from 
15°C to -2,5°C. The growth kinetic parameters of the bacterium in GG medium at 
subzero temperature confirm that the Antarctic bacterium is well adapted to cold 
environment and pave the way to the definition of strategies, used by P. haloplanktis 
TAC125, to face sub-zero temperature conditions. Moreover, in this paper we reports 
the setup of a finely regulated expression system inducible by D-galactose to 
produce recombinant protein in GG synthetic medium at low temperatures. Thanks to 
the new expression systems we obtained, for the first time, the production of a 
recombinant protein at minus 2,5°C, providing a new tool for investigating basic 
science issues and for the recombinant production of “difficult” proteins. 
 
Keywords 
 
P.haloplanktis TAC125, sub-zero growth temperature, recombinant protein 
production, cold-adapted bacteria. 
 
Introduction  
 
Pseudoalteromonas haloplanktis TAC125 (P. haloplanktis TAC125), a Gram-
negative psychrotolerant marine bacterium,  is one of the best studied cultivable 
representatives of the marine bacterioplankton and it can be considered a model 
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organisms of cold-adapted bacteria (Medigue et al. 2005; Feller et al 2003). Indeed, 
the increasing interest in P. haloplanktis TAC125 has led to the accumulation of 
different data types for this bacterium in the last few years, including its complete 
genome sequence (Medigue et al. 2005), its proteome (Piette et al. 2010; Piette et al. 
2011), detailed growth phenotypes (Wilmes et al., 2010; Giuliani, 2011) and a 
genome scale metabolic model (Fondi et al 2015). 
Genomic and metabolic features of this bacterium, accounting for its notable 
versatility and fast growth compared with other bacteria from marine environments, 
were revealed by combining genome sequencing and further in silico and in vivo 
studies. It is worth mentioning that the bacterium is well adapted to protection against 
reactive oxygen species (ROS) under cold condition (Wilmes et al. 2010; Parrilli et al. 
2010a). Moreover the in silico proteome composition revealed a speciﬁc bias that is 
responsible for its ability to resist to protein aging features involving asparagine 
cyclization and deamidation (Weintraub and Manson 2004). The bacterial genome is 
characterized by a quite high number of rRNA and tRNA genes, which may account 
for its relevant capacity for translation in the cold (Medigue et al., 2005).  
P. haloplanktis TAC125 was also the ﬁrst Antarctic bacterium in which an efﬁcient 
gene-expression technology was set up (Parrilli et al. 2008a). Several generations of 
cold-adapted gene-expression vectors allow the production of recombinant proteins 
either by constitutive or inducible systems (Papa et al. 2007; Giuliani et al. 2011 ), 
and to address the product towards any cell compartment or to the extra-cellular 
medium (Parrilli et al. 2008b). This cold-adapted protein production platform, 
compared to the conventional mesophilic E. coli, offers favourable effects described 
during the production of some “difﬁcult proteins”, such as: antibody fragments 
(Dragosits et al. 2011; Giuliani et al. 2011; Giuliani et al. 2014; Giuliani et al. 2015), 
human nerve growth factor (h-NGF), (Vigentini et al. 2006), alpha-glucosidase from 
S. cerevisiae (Papa et al. 2007) and human alpha-galactosidase (Unzueta et al. 
2015). The versatility of P. haloplanktis TAC125 as host for recombinant protein 
production was widened by the development of an efﬁcient genetic scheme, allowing 
the construction of genome targeted insertion/deletion mutants and permitting to 
create genetically engineered strains with improved features regarding protein 
production (Parrilli et al. 2010b). 
Besides the above mentioned use of P. haloplanktis TAC125 as cell factory for 
recombinant protein production, the bacterium does share with many other 
Pseudoalteromonales the striking ability to produce bioactive secondary metabolites 
of biotechnological relevance, such as anti-biofilm molecules (Papa et al. 2013; 
Parrilli et al. 2015) and volatile organic compounds (VOCs), active against a group of 
human opportunistic pathogen called Burkholderia cepacia complex (Bcc) (Papaleo 
et al. 2013).  
In order to widen and deeply explore the P. haloplanktis TAC125 potentiality as 
source of bioactive compounds and non-conventional systems for the recombinant 
protein production, it is necessary to develop a synthetic medium for growth at low 
temperature. The definition of a low cost synthetic medium is the requirement for 
scale up of the P. haloplanktis TAC125 growth in automatic bioreactors. Moreover, a 
defined “minimum” medium could enhances the secondary metabolites production 
and it surely makes their purification from extracellular medium easier.  
P. haloplanktis TAC125 does not possess a phosphoenolpyruvate-dependent 
phosphotransferase system (PTS) for the transport and first metabolic step of 
carbohydrate degradation (Medigue et al. 2005) therefore it does not grow on D-
glucose, and it doesn’t grow on glucose related sugars (e.g. D-fructose or D-xylose) 
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(Papa et al. 2006). The Antarctic bacterium seems to be well adapted to growth on 
rich media containing amino acids, used as carbon and nitrogen source. Genomic 
(Medigue et al. 2005) and proteomic (Wilmes et al. 2010) analysis reveals the 
presence of all metabolic pathways for amino acids biosynthesis and degradation. 
Starting from this observation, a defined medium composed by L-leucine, L-
isoleucine and L-valine (LIV) was previously formulated and optimised for the 
production of recombinant proteins (Giuliani et al. 2011). LIV medium allowed an 
over sevenfold increase of reporter enzyme production and threefold of biomass yield 
with respect to the previously optimized conditions, moreover the synthetic medium 
was also tested for the production of a recombinant antibody fragment in batch and 
chemostat cultivations (Giuliani et al. 2011). However, in this synthetic medium P. 
haloplanktis TAC125 displays a very low specific growth rate already at 4°C (Giuliani 
et al 2011) and it is no able to grow at lower temperature. This is a severe limit either 
for the use of Antarctic bacterium as host for recombinant protein production or as 
source of bioactive compounds. Moreover, the use of L-leucine, L-isoleucine and L-
valine substrates is unprofitable for a large scale production process due their high 
cost and their very poor solubility in water. 
 
Materials and methods 
 
Bacterial strains and culture conditions  
 
Escherichia coli DH5α [supE44, ΔlacU169 (Φ80 lacZΔM15) hsdR17, recA1, endA1, 
gyrA96, thi-1, relA1] (Hanahan 1983) was used as host for the gene cloning. E. coli 
strain S17-1(λpir) [thi, pro, hsd (r- m+) recA::RP4-2-TCr::Mu Kmr::Tn7, Tpr, Smr, λpir] 
(Tascon 1993) was used as donor in intergeneric conjugation experiments (Parrilli et 
al 2008a). E. coli cells were routinely grown in LB broth containing 100 µg mL-1 of 
ampicillin if transformed. 
The Gram-negative Antarctic bacterial strain P. haloplanktis TAC125 was isolated 
from Antarctic sea water (Medigue et al., 2005) and it is deposited and available at 
the Institut Pasteur Collection (CIP 108707). TAC125. Different media were used for 
the P. haloplanktis cultivations: 1) D-Gluconate 5-10-20 g L-1 as single carbon 
source, 2) L-Glutamate 10g L-1 as single carbon and nitrogen source 3) GG medium 
(L-glutamate 10 g L-1, D-gluconate 10 g L-1). All media was complemented with a 
marine salts mix K2HPO4 1 gL-1 10 g L
-1 NaCl, 1 g L-1 NH4NO3, 200 mg L
-1 
MgSO4·7H2O, 5 mg L
-1 FeSO4·7H2O, 5 mg L
-1 CaCl2·2H2O resulting in a final of pH 
7.5. 
The bacterium was grown in GG at various temperatures (15, 4, 0 -2,5°C) with 
shaking at 250 rpm in Nüve-Cooled incubator (model ES120). Absorbance at 600 nm 
was monitored over time. Growth rates at exponential phase were calculated by 
standard methods. 
Recombinant strain P. haloplanktis TAC125 (pMAV-lacZ) was grown in GG medium 
in presence of 100 µg mL-1 ampicillin (Sigma) at 15°C and 4°C, and in presence of 50 
µgmL-1 ampicillin (Sigma) at 0°C and -2,5°C.  
 
Biomass determination  
 
For biomass determination suitable sample volumes were washed in demineralised 
water, collected and dried on pre-weighed filter paper discs and dried at 110°C until 
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constant weight. The dry cell weight was correlated with OD at 600nm throughout the 
following equation: 
At 15°C Dry cell weight (g L-1) = 0,74 x OD600nm 
At 4°C Dry cell weight (g L-1) =0.74 x OD600nm 
At 0°C Dry cell weight (g L-1) = 0,66 x OD600nm 
At -2.5°C Dry cell weight (g L-1) =0,41 x OD600nm 
 
Construction of pMAV and pMAV-lacZ plasmids 
 
DNA manipulation and analysis were performed according to standard methods 
(Sambrook and Russell 2001). Plasmidic DNA extraction and fragments purification 
are carried out with the QIAprep Spin Miniprep Kit and Qiaquick gel extraction kit 
from Qiagen, respectively. Restriction enzymes, T4 DNA ligase, alkaline 
phosphatase, Phusion High-Fidelity DNA Polymerase were supplied by Promega, 
Boehringer-Roche, Fermentas or Finnzyme. 
The galTK operon upstream region was amplified from P. haloplanktis TAC125 
genome by polymerase chain reaction (PCR).  
The primers used mavfw (5’-ACACAAGCTTATGGGCTATTTTTGATACTC-3’ ) and 
mavrv (5’-GCGCCATATGAAGTATCTCAAATGTGG-3’) were designed on the basis 
of the P.  haloplanktis TAC125-genome sequence and sequences corresponding to 
the HindIII site and a NdeI site were introduced in the forward and reverse primers, 
respectively. 
The amplifications were performed in a mixture containing 80 ng of P. haloplanktis 
TAC125-genomic DNA as template, 50 pmol of each oligonucleotide primer, 1.8 mM 
MgCl2, 50 mM KCl, 20 mM Tris-HCl pH 8.3, 0.1% gelatine, 200 µM dNTP in a final 
volume of 50 µl. The mixtures were incubated at 95°C for 10 min, then 1.25 units of 
Taq DNA polymerase were added. Twenty cycles of amplification (consisting in 1 min 
at 95°C, 1.5 min at 60°C and 1 min plus 5sec/cycle at 72°C) were carried out and 
followed by a cycle in which the extension reaction at 72°C was prolonged for 15 min 
in order to complete DNA synthesis. The amplified fragment was cloned and its 
nucleotide sequence checked to rule out the occurrence of any mutation during 
synthesis.  
The amplified region (MAV promoter) was hydrolysed with Hind III restriction enzyme 
and a fill in reaction at the 3’ extremity was performed, after that a NdeI hydrolysis 
was performed. The amplified region was cloned into a psycrophilic vector. In detail, 
the pPM13 plasmid (Duilio et al. 2004) was hydrolysed with EcoRV and NdeI 
restriction enzymes in order to remove the DNA fragment corresponding to promoter 
13 and to introduce MAV promoter.  The fragment amplified region was subcloned 
into pPM13  obtaining the plasmid pMAV. 
A fragment (964 bp) of psychrophilic lacZ was amplified from cloneQ-lacZ(ref) 
plasmid by polymerase chain reaction (PCR).  
The primers used were galfw (5’-AGCACATATGACCTCTTTACAGCAC-3’) and galrv 
(5’-TGTTATAGGCTTCAACGTCGACTG-3’ ) and sequences corresponding to the 
NdeI site and a SalI site were introduced in the forward and reverse primers, 
respectively. The amplified fragment was hydrolysed with NdeI and SalI restriction 
enzymes. The cloneQ-lacZ plasmid was hydrolysed with SalI and PstI restriction 
enzymes to obtain the remaining fragment of the psychrophilic lacZ gene. The pMAV 
plasmid was hydrolysed with NdeI and PstI restriction enzymes and a ligase was 
performed to clone the two fragments of the psychrophilic lacZ gene in pMAV 
plasmid. The resulting pMAV-lacZ plasmid was verified by DNA sequencing.  
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RNA preparation and RT  
 
Total RNA was isolated from pellets corresponding to 500 µl of P. haloplanktis 
TAC125 cell culture (RNasy Mini kit, Qiagen) and subjected to in-column DNase 
treatment (Rnase-Free Dnase Set, Qiagen). Quality of the RNA isolation was 
checked by gel electrophoresis followed by quantification in spectrophotometer 
according to Sambrook and Russell, 2001. Only samples showing a A260nm/A 
280nm ratio = 0,8 were used for further experiments. Reverse transcription (RT) 
reactions were performed using SuperScript II RNase H Reverse Transcriptase 
(Invitrogen) according to the manufacturer's instructions using 100 pmol of specific 
primers on approximately 5 µg of total purified RNA. In addition, RT negative control 
reactions were performed where water was added instead of template.  
 
Analysis of mRNA by qRT-PCR  
 
The qRT-PCR method was used to determine the relative amount of specific 
transcriptional products in the presence/absence of 10 mM D-galactose. The qRT-
PCR was performed with cDNAs prepared from 2 separate cultures per treatment. 
Each of the four cDNA samples obtained was amplified in triplicate experiments. A 
total of 12 data were obtained. 
Real-time PCR was carried out using a StepOne™ Real Time PCR System  (Applied 
Biosystems) and the amplification of the target sequences was detected using SYBR 
-Green technology. The housekeeping gene ihfB was chosen as an internal control to 
correct for variations of mRNA amounts and cDNA synthesis efficiency. 
The primers for specific amplification were designed by Primer Express 
SoftwareVersion 3.0 (Applied Biosystems) IhfB-fw-PSHAa1426 5’-
TTGAGATCAGAGGTTTTGGTAGTTTTT-3’, IhfB-rv-PSHAa1426 5’-
TTCGCCAGTCTTAGGGTTACG-3’, LacZ-fw 5’_CCTTCTCGCCCAGTGCAA-3’, 
 LacZ-rv 5’-CGGGAGTACATTGGGCAAAT-3’) qRT-PCR amplification mixtures 
(20 µl) contained 2 µl template cDNA, 2x SYBR® Green I Master Mix (10 µl) (Applied 
Biosystems) and 300 nM forward and reverse primer. A non-template control reaction 
mixture was included for each gene. The PCR cycling programme was as follows: 
holding stage, 1 cycle of 95°C for 10 min; cycling stage, 40 cycles at 95°C for 15 s, 
60°C for 60 s; melting curve stage 1 cycle at 95°C for 15 s, 60°C for 60 s, 95°C for 15 
s with a temperature increment of +0,3°C. Specificity of the reaction was checked by 
analysis of the melting curve of the final amplified product. Experiments and data 
analysis were performed using StepOne™ Software v2.0 by ΔΔCt method (Applied 
Biosystems User Bulletin, 1997).  
 
Cell lysis and enzymatic assays  
 
For recombinant β-galactosidase production analysis aliquots of bacterial pellet 
corresponding to 1 mL culture volume were resuspended in 1mL Lysis buffer (Na 
phosphate buffer 0,1M pH 7,8, EDTA 2 mM, DTT 1 mM, Triton X-100 1% v/v, 
lisozyme 5 mg mL-1, PMSF 1 mM) and incubated at 15°C for 30’. The suspension 
was then centrifuged at 10000 rpm for 15 mins at 4°C and the supernatant used for 
activity assays.  
Recombinant cold-active β-galactosidase was assayed spectrophotometrically at 
25°C as previously reported (Hoyoux et al. 2001). Calculation were performed on the 
basis of the extinction coefficient for o-nitrophenol at 410 nm (3.5mM−1 cm−1) and the 
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specific activity of purified enzyme, 138.2 U mg-1 (Hoyoux et al. 2001). Kinetics were 
registered with a DU7500 spectrophotometer (Beckman). Protein concentration was 
determined with the Bio-Rad protein assay (Bradford, 1976), using bovine serum 
albumin as standard.  
 
Determination of concentration of D-Gluconate and L-Glutamate 
 
Aliquots of the supernatant deriving from cell cultures were assayed to determine the 
concentration of D-gluconate, and L-glutamate residue, by Megazyme kits D-gluconic 
acid/ D-glucono-δ-lactone k-gate 11/05l and L-glutamic acid k-glut 03/06. 
 
Statistic calculation 
 
Data are reported as means of at least four independent experiments  with its 
uncertainty s expressed as standard deviations. Propagation of errors was calculated 
using simpler average errors (add all the relative errors to get the relative error in the 
result). 
 
Results 
 
Selection of suitable carbon sources 
 
Previously reported data (Wilmes et al. 2010; Giuliani et al. 2011) suggested that 
sodium glutamate is an important carbon and nitrogen source for P. haloplanktis 
TAC125. Therefore we started our search of suitable carbon sources focusing our 
attention on L-glutamate. Our analysis was firstly focused on glutamate uptake 
system in the Antarctic bacterium, in silico genome scanning pointed to a putative 
sodium dependent transporter gene (PSHAa2084, a glutamate transporter PhGltS). 
This gene displays an 47% sequence identity with V. cholerae glutamate transporter 
and 30% sequence identity with Aphanothece halophytica AhGltS gene coding for a 
L-glutamate sodium dependent carrier (Boonburapong et al. 2012). In order to 
assess if in P. haloplanktis TAC125 the glutamate uptake is sodium dependent we 
analyzed the bacterium growth performance in three different media differing in NaCl 
concentration (5, 10, 15 g L-1). As shown in Table S1 the speciﬁc growth rate 
depends on NaCl concentration used in growth medium., at least in the range 
between 5 and 10 g L-1 . The biomass yields in the three media is almost the same 
indicating that the NaCl concentration influences only the glutamate uptake and 
suggests that PhTAC125 GltS transporter is sodium dependent . Since the growth 
parameters recorded in presence of 15 or 10 gL-1 NaCl resulted to be identical, we 
choose as salt source a mineral medium (see material and methods section) that 
contains NaCl 10gL-1 . 
The analysis of P. haloplanktis TAC125 genome highlighted the occurrence of the 
Entner-Doudoroff pathway (Medigue et al. 2005) as central catabolic pathway for 
carbon metabolism. In silico analysis revealed that genes for all enzymatic functions 
required in Entner-Doudoroff pathway are present in P. haloplanktis TAC125 
genome. In order to evaluate the P. haloplanktis TAC125 growth performances in a 
medium containing D-gluconate as sole carbon and energy source, we analysed 
three media differing in D-gluconate concentration. As reported in Table S1 P. 
haloplanktis TAC125 is able to growth in a mineral medium supplemented with 
gluconate, and the gluconate concentration has no evident effect on specific growth 
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rate and has only a slight positive effect on the maximum biomass obtained (Table 
S1). 
Also in case of glutamate uptake, an in silico analysis of P. haloplanktis TAC125 
genome was carried out. D-gluconate is likely to be uptaken from the medium by a 
gluconate transporter, encoded by the PSHAb0479 gene, homologous to E. coli 
GntU (Izu et al. 1997). In E. coli gntU is repressed by GntR in the absence of 
gluconate. As P. haloplanktis genome contains a gntR homologous, PSHAb0478, a 
real time PCR analysis of PSHAb0479 transcription demonstrated its expression  
only in the presence of D-gluconate in the medium (data not shown). 
 
GG Medium  
 
Numerous trials have been carried out looking for the best combination between L-
glutamate, D-gluconate, other mineral nutrients and final pH value. The medium that 
led to the best growth performance was named GG (mineral medium supplemented 
with 10g L-1 L-glutamate and 10g L-1 D-gluconate, see material and methods). As 
shown in Fig.1, P. haloplanktis TAC125 growth profiles at 15°C and 4° C in GG are 
characterized by the absence of lag phase and by a simultaneous consumption of 
the two substrates, a condition which allows its use for a fed-batch process 
development. As reported in Table 1 the GG medium resulted to be more efficient 
than medium containing only either L-glutamate or D-gluconate, in terms of biomass 
yields. This improvement is more noticeable at 4°C, at this temperature Antarctic 
bacterium was able to growth with a biomass yields of 0,44, thus indicating that GG 
medium is suitable for P. haloplanktis TAC125 growth at low temperature.  
 
P. haloplanktis TAC125 growth in GG at sub-zero temperature 
 
As previously described (Medigue et al. 2005) a remarkable feature of P. haloplanktis 
TAC125 is that, when provided with sufficient nutrients and aeration, it grows to very 
high density under laboratory settings, even at 0°C. Since in GG P. haloplanktis 
TAC125 was able to growth with a good biomass yield and speciﬁc growth rate at 
4°C, we tested the Antarctic bacterium growth at lower temperatures i.e. at 0°C and 
at -2,5°C (Fig. S1) and the recorded growth parameters are shown in Table 1, in the 
synthetic medium P. haloplanktis TAC125 was able to growth at 0°C and at –2,5°C 
also. Surprisingly when grown at 0°C P. haloplanktis TAC125 reaches a biomass 
concentration higher than that obtained growing the bacterium in media containing 
only L-glutamate at 15°C or at 4°C. Moreover, speciﬁc growth rate at -2,5°C is 
comparable with the value obtained growing P. haloplanktis TAC125 in media 
containing only D-gluconate at 4°C (Table 1). 
 
Construction of a novel psychrophilic inducible gene expression system 
(pMAV) for recombinant protein production in GG medium 
 
To enlarge P. haloplanktis TAC125 available genetic tools for the recombinant 
protein production system, it is necessary to set up a finely regulated expression 
system to allow the production of toxic proteins for the host cells. This goal can be 
achieved by the identification of new regulated psychrophilic promoter to be used in 
the new synthetic medium GG.  
P. haloplanktis TAC125 is able to grow on mineral medium containing D-galactose 
(data not shown) thus indicating the presence of a functional Leloir pathway (Frey et 
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al. 1996), which catalyses the conversion of D-galactose to the more metabolically 
useful version of the sugar, D-glucose-6-phosphate. Aiming at the identification of 
new regulated promoters, the regulation of genes responsible for D-galactose 
catabolism in P. haloplanktis TAC125 was studied in silico. In E. coli, the genes 
responsible for D-galactose metabolism (galETKM operon) and for its high affinity 
transport (mglBAC operon) are repressed, in absence of D-galactose, by the 
repressor GalR and the isorepressor GalS (Weickert and Adhya 1993; Von Wilcken-
Bergmann and Muller-Hill 1982). In P. haloplanktis TAC125 gal operon shows a 
different organisation compared to the one of E. coli,  the PhgalE gene (PSHAa0469) 
is not included in the cluster and between PhgalK and PhgalM there is a gene 
(PSHAa1768) predicted to encode a putative sodium/hexose co-transport protein 
(Fig.2). Moreover a galR homologous was found showing 42,7% identity to EcgalR, 
this gene, named PhgalR (PSHAa1771) is located downstream the galT sequence in 
the opposite direction (Fig. 2). In P. haloplanktis TAC125 genome neither the 
mglBAC operon nor the galS isorepressor are present. The intergenic distances 
between P. haloplanktis TAC125 gal genes could suggest that only galT and galK 
can be included in gal operon. Those two genes are in fact overlapped (-1bp 
distance) showing the typical intergenic region structure of translationally coupled P. 
haloplanktis TAC125 genes. Starting from the above consideration, we decided to 
construct an expression vector using the DNA region upstream PhgalTK operon, the 
DNA sequence containing PhgalTK promoter and the gene coding for PhGalR (Fig. 
2) the resulting region was called MAV promoter. 
The MAV promoter region was suitably PCR-amplified and used to construct the 
psychrophilic pMAV vector. In order to assess if pMAV expression system was finely 
regulated by D-galactose, lacZ gene, coding for cold-adapted  β-galactosidase from 
Pseudoalteromonas haloplanktis TAE 79 (Hoyoux et al. 2001), was cloned under the 
control of MAV promoter (see Material and Methods section). Then P. haloplanktis 
TAC125 (pMAV-lacZ ) recombinant cells were grown both in the presence and in 
absence of 5g L-1 D-galactose (28 mM) in the GG medium, at 15°C. A real-time PCR 
was performed, to compare the relative amount of lacZ mRNA produced both in the 
presence and in the absence of D-galactose (Fig. 3). In absence of D-galactose the 
lacZ transcript was almost negligible, while it was observed a 40-fold enhancement 
upon induction (Fig. 3). 
P. haloplanktis TAC125 pMAV-lacZ recombinant strain was grown in GG in the 
absence and in the presence of 10 mM D-galactose, added at middle exponential 
phase, at different temperatures and β-galactosidase catalytic activity was assayed in 
the cell lysates as previously described (Hoyoux et al. 2001). In absence of the 
inducer no β-galactosidase activity was recorded. As reported in Table 2 recombinant 
β-galactosidase is produced at all tested temperatures and surprisingly at 0°C  the  
production yield is comparable with that obtained at 15°C and 4°C. 
 
Discussion 
 
Previously reported data (Wilmes et al 2010; Giuliani et al 2011) suggested that 
sodium glutamate is an important carbon and nitrogen source for P. haloplanktis 
TAC125. Therefore we started our search of suitable carbon sources for P. 
haloplanktis TAC125 focusing our attention on L-glutamate, although reported results 
confirmed the validity of glutamate as carbon and nitrogen source, we formulated a 
new medium adding the gluconate to glutamate. 
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The ED route is proﬁcient in generation of reducing power, in particular NADPH 
(Conway et al. 1992; Kim et al. 2008), this cofactor has many metabolic functions, 
out of which synthesis of various amino acids and counteracting oxidative stress 
predominate (Chavarría et al. 2013; Singh et al. 2007). As oxygen solubility 
increases with a decline in temperature, the employment of a ED substrate for P. 
haloplanktis TAC125 growth may represent a feasible means, not only for the 
production of energy (ATP) and generation of various building blocks for cellular 
functions, but also for providing the organism with better oxidative stress adaptation 
under low-temperatures life. These observations prompted us to test D-gluconate as 
carbon source for P. haloplanktis TAC125, and to formulate a new medium 
combining D-gluconate and L-glutamate. In detail, glutamate catabolism provides the 
bulk of cellular energy and various building blocks for cellular functions through TCA, 
while gluconate metabolism provides a reductive environment (generating NADPH) 
to nullify the reactive oxygen species (Singh et al. 2007). In GG the Antarctic 
bacterium resulted to be able to growth at 4°C with the best biomass yield ever 
reported (0,44), and to efficiently grow at sub-zero temperatures (0°C and -2.5°C), 
displaying a doubling time of about 23h at -2,5°C. In previously reported papers 
(Nunnet al. 2015; Mykytczuk et al. 2013 ) describing bacteria growth at sub-zero 
temperature the time reported for duplication are usually several weeks, these results 
clearly confirm that P. haloplanktis TAC125 is well adapted to cold environment and 
suggest that GG medium allows a fine balance between NADPH, ATP and NADH in 
P. haloplanktis TAC125 cells at low temperature. GG medium is the first, to the best 
of knowledge, described synthetic medium used to characterize growth kinetic 
parameter of bacterium in pure culture at subzero temperature and it will be 
fundamental in the definition of strategies, used by P. haloplanktis TAC125, to face 
sub-zero temperature conditions. Moreover, surely GG medium will be decisive to 
deeply explore the P. haloplanktis TAC125 potentiality as source of bioactive 
molecules allowing the analysis of never described secondary metabolites produced 
at 0 °C and -2.5°C.  
In order to exploit GG synthetic medium not only for physiologic studies but also for 
the recombinant protein production, a suitable expression system was constructed. 
The development of an cold expression system to produce recombinant protein at 
sub-zero temperature needed an ad hoc regulated promoter since previously 
described P. haloplanktis TAC125 genetic systems (Papa et al. 2007; Giuliani et al. 
2011) resulted to be not compatible with GG medium. As previously reported in 
Giuliani et al. 2011, the L-malate inducible psychrophilic expression system (Papa et 
al. 2007 ) in presence of L-glutamate is not functional and a negative interference 
between the L-glutamate and L-malate (the inducer) was suggested. Transcription 
activation by L-malate is also inhibited when L-glutamate are used in combination 
with other amino acid (Giuliani et al. 2011). 
Aiming at the identification of new regulated promoters, the analysis of P. 
haloplanktis TAC125 genome was carried out in order to identify genes and/or 
operons whose transcription is expected to be up-regulated in the presence of 
particular carbon sources. This kind of analysis was not easy since in bacteria genes 
involved in primary metabolism processes are generally finely regulated in response 
to the nutrients availability, but in environments were excess of several easily 
metabolised carbon sources are present simultaneously, it is unlikely, as in Antarctic 
sae water, that the catabolite repression is an the exception rather than the rule. Our 
attention was captured by genes involved in D-galactose catabolism since our 
unpublished results clearly indicate that P. haloplanktis TAC125 is able to grow on D-
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galactose (data not shown), thus indicating the presence of a functional Leloir 
pathway (Frey et al. 1996). The analysis indicated in P. haloplanktis TAC125 the 
presence of a gal gene cluster with a different structural organisation compared to 
best studied E. coli one. In the mesophilic bacterium, the transcription regulation of 
gal operon is complex (Lewis and Adhya 2015) and involve cAMP, its receptor 
protein CRP, and GalS, all components that are not present in P. haloplanktis 
TAC125 genome. However, the Antarctic bacterium possess a gene coding for a E. 
coli GalR homologue, PhgalR (PSHAa1771), which is located upstream the PhgalT 
but in the opposite direction. In order to obtain a finely regulated expression system, 
DNA sequence containing galTK promoter and the gene coding for PhGalR was 
cloned in the pMAV vector. The new expression system resulted to be repressed in 
absence and induced in presence of D-galactose, and therefore it could be used for 
the production of toxic proteins for the host cells. In this paper the new expression 
system was used to produce a cold-adapted β-galactosidase at different 
temperatures from 15°C to -2,5°C, surprisingly at 0°C we obtained more enzyme that 
at 4°C. Although this surprising result could be due to several factors, in any case it is 
reasonable to think that optimal induction conditions (different amount of D-
galactose, growth induction phase. time of induction ecc,…) may be different for each 
growth temperature and have to be defined. However, the expression system 
described in this paper (GG medium and pMAV vector) allowed, for the first time, the 
recombinant protein production at sub-zero temperature, this result not only will be 
used to further investigate some basic science issues, i.e the relation between 
protein folding and temperature, but will be instrumental for the recombinant 
production of “difficult” proteins. As previously reported (Corcero et al; Piette et al. 
2010), cellular physicochemical conditions and/or folding processes in P. haloplanktis 
TAC125 are quite different from those observed in canonical mesophilic hosts, 
therefore the possibility to produce proteins at a range of temperature from 15°C to -
2.5°C enhance the chances to improve the conformational quality and solubility of 
difficult-to-express protein products. 
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TABLES: 
 
Table 1: P. haloplanktis specific growth rate (µmax), maximum biomass 
concentration, biomassa yield (Yx/s) in selected synthetic media. Means and 
standard deviations have been calculated from four independent experiments; . ±: 
standard error of the mean; dcw stands for dry cell weight; * values obtained by error 
propagation procedure and assuming that the g carbon source are 10g±0,1 (in case 
of medium containg gluconate or glutammate only) and 20g.±0,1 in case of GG 
medium. 
 
Temperature Medium 
µmax 
(h
-1
) 
maximum 
biomass 
concentration 
(gdcw L
-1
) 
Yx/s 
(gdcw gcarbon 
source
−1
) 
15°C 10 g L
-1
 L-glutamate 0,23±0,03 2,44±0,07 0,24±0,07* 
4°C 10 g L
-1
 L-glutamate 0,087±0,02 3,65±0,013 0,365±0,011* 
15°C 10 g L
-1
 D-gluconate 0,13±0,02 1,63±0,03 0,16±0,004* 
4°C 10 g L
-1
 D-gluconate 0,035±0,005 2,05±0,014 0,05±0,003* 
15°C GG 0,28±0,02 5,40±0,01 0,27±0,03* 
4°C GG 0,16±0,01 8,89±0,03 0,44±0,05* 
0°C GG 0,037±0,002 3,20±0,03 0,16±0,03* 
-2.5° GG 0,030±0,002 1,86±0,06 0,093±0,004* 
 
Table 2: Recombinant β-galactosidase production at different temperatures: β-
galactosidase activity recovered in cell extracts of P. haloplanktis TAC125 (pMAV-
LacZ) cells grown in GG in shaken flasks at 4°C, 15°C, 0°C and -2,5°C. 
Galactosidase induction was performed by 10mM D-galactose addition in middle 
exponential phase, samples were collected 24 h after in case of P. haloplanktis 
TAC125 (pMAV-LacZ) growth at 4°C and15°C., after 72h at 0°C and after 120h at -
2,5°C. Means and standard deviations have been calculated from three independent 
assays. ±: standard error of the mean; dcw: dry cell weight;* values obtained by error 
propagation procedure. 
 
Temperature 
[β-gal]  
(mg L-1) 
final biomass 
concentration  
(g L-1) 
YP/X  
(g gdcw−1) 
15°C 119,3±0,1 1,85±0,1 0,064±0,003* 
4°C 34,5±0,1 1,80±0,3 0,02±0,003* 
0°C 82,84±0,8 1,65±0,1 0,05±0,003* 
-2,5°C 6,52±0,01 1,22±0,2 0,0051±0,008* 
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FIGURE 
 
Fig. 1: Growth of P.halopanktis TAC125 in GG medium at 15°C and 4°C:  
Panel a, P.haloplanktis TAC125 growth profile at 15°C in GG. The black line 
indicates growth profile at 15°C, the gray continue line shows L-glutamate 
consumption, the black hatched line shows D-gluconate consumption. 
Panel b, P.haloplanktis TAC125 growth profile at 4°C in GG. The black line indicates 
growth profile at 4°C, the gray continue line shows L-glutamate consumption, the 
black hatched line shows D-gluconate consumption. 
 
 
 
 
 
 
Fig. 2: Schematic organization of in P.haloplanktis TAC125 gal operon, the region 
PCR amplified and cloned in pMAV is highlighted. OriC: pUC18-derived origin of 
replication; OriR: pMtBL-derived autonomous replication sequence; AmpR-β-
lactamase encoding gene; OriT: conjugational DNA transfer origin; Tasp, PhTAC125 
aspC transcriptional terminator; MAV DNA sequence containing galTK promoter and 
the gene coding for PhGalR.  
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Fig. 3: Real Time PCR relative quantification of P. haloplanktis TAC125 (pMAV-lacZ) 
at 15°C in GG when induced by galactose. On X-axis are reported lacZ mRNA in the 
presence (+) or absence (-) of D-galactose, an Y-axis are reported the relative 
quantification RQ.  
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SUPPLEMENTARY MATHERIAL 
 
Fig. S1: Growth profile of P.halopanktis TAC125 in GG at 0 °C and -2,5°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
MANUSCRIPT SUBMITTED TO NEW BIOTECHNOLOGY_____________________ 
Pseudoalteromonas haloplanktis produces methylamine, a volatile compound 
active against Burkholderia cepacia complex strains 
 
Filomena Sannino
1
, Ermenegilda Parrilli
1
, Gennaro Antonio Apuzzo
1
, Donatella de Pascale
2
, Pietro 
Tedesco
2
, Isabel Maida
3
, Elena Perrin
3
, Marco Fondi
3
, Renato Fani
3
, Gennaro Marino
1
 and Maria 
Luisa Tutino
1,
* 
 
1,* 
Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario 
Monte Sant’Angelo, Via Cinthia, 80126 Napoli- Italy; E-Mail: filomena.sannino2@unina.it; 
gen.apuzzo@gmail.com; erparril@unina.it ; gmarino@unina.it; tutino@unina.it 
 
2 
Institute of Protein Biochemistry, National Research Council, Via Pietro Castellino, 111, 80126 
Naples-Italy; E-Mail: d.depascale@ibp.cnr.it ; p.tedesco@ibp.cnr.it
 
3 
Laboratory of Microbial and Molecular Evolution, Department of Biology, University of 
Florence, via Madonna del Piano 6, I-50018 Sesto F.no (Florence), Italy; E-Mail: isabel.maida@unifi.it 
; marco.fondi@unifi.it; renato.fani@unifi.it; elena.perrin@unifi.it;  
* Author to whom correspondence should be addressed; E-mail: tutino@unina.it;  
Tel.: +39-081-674317; Fax: +39-081-674313.  
 
Abstract: 
The Antarctic marine bacterium Pseudoalteromonas haloplanktis TAC125 has been 
reported to produce several Volatile Organic Compounds (VOCs), which are able to 
inhibit the growth of Burkholderia cepacia complex (Bcc) strains, opportunistic 
pathogens infecting immune-compromised patients. Growth media composition 
influenced the produced VOCs profiles and, conversely, effectiveness and number of 
pathogen strains inhibited. In this paper we report the definition of a synthetic 
medium (containing D-gluconate and L-glutamate as carbon and energy sources), in 
which the Antarctic bacterium displays good growth parameters but is unable to 
inhibit Bcc strains. The single addition of several amino acids to the medium restores 
the P. haloplanktis TAC125 inhibition ability. Therefore, with the aim of identifying 
specific volatile compound/s responsible for Bcc inhibition, we used a methodology 
for VOCs capture, accumulation, and storage by coupling the growth of the Antarctic 
bacterium in an automatic fermenter with the application of a cooling system to the 
exhaust air outlet. This approach allowed the identification of methylamine as a VOC 
produced by P. haloplanktis TAC125 when grown in the synthetic medium 
supplemented with methionine and demonstrated that this molecule is able to inhibit 
the growth of several Bcc strains in dose-dependent way. This is the first paper in 
which the antibacterial effect of one specific identified volatile compound produced by 
an Antarctic marine bacterium was demonstrated. 
 
Keywords: Pseudoalteromonas haloplanktis TAC125, methylamine, Volatile organic 
compounds, Burkholderia cepacia complex 
 
Introduction: 
Microbial resistance to antibiotics has spread dramatically in the last 50 years, 
leading to an increasing number of deaths due to infectious diseases. The massive 
and often inappropriate use of antibiotics in hospitals and in livestock industries led to 
the creation of a group of multi-drug Resistant (MDR) microorganisms, which 
represent a major global health issue [1]. Hence, there is an urgent need to identify 
novel antibiotics to counteract these hazardous microorganisms [2, 3]; in this context 
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the discovery of novel natural drugs might represent one of the possible solutions. 
Indeed, natural products have been the main source of antibacterial drugs in the 
past, and today they still represent the two-third of the new antibiotics released in the 
last 20 years [4, 5].  
Particular interest for biotechnological applications are the inhibitory effects of 
microbial volatiles compounds against the growth of the others microorganisms.  
Volatile Organic Compounds (VOCs) are a class of heterogeneous natural molecules 
that have recently acquired a notable interest. Various bacteria from different 
environments synthesise VOCs [6, 7] through both primary and secondary metabolic 
pathways; however, their biological function has not been clearly defined yet. It was 
initially proposed that these compounds might represent waste material or end 
products of various biological processes. Further studies demonstrated that VOCs 
are able to influence the growth of other bacteria, in a sort of chemical at-a-distance 
cross-talk [8, 7]. 
We have previously demonstrated that marine Antarctic bacteria belonging to 
different genera/species are able to synthesise VOCs of different chemical classes, 
including sulphur compounds [9, 10, 11, 12,]. Interestingly, VOCs synthesised by 
several Antarctic bacteria specifically inhibit the growth on solid media of strains 
belonging to the Burkholderia cepacia complex (Bcc) [9, 10, 11], a group of 
opportunistic human pathogens most of which characterized by multi drug resistance. 
Outcomes from our previous reports demonstrated that VOCs are constitutively 
synthesised by Antarctic bacteria [11] and that Antarctic strains belonging to different 
species/genera apparently synthesize the same VOCs, as their respective VOCs 
profiles are quite similar [9, 11]. Interestingly, relative concentration of each VOC 
may vary between different strains [9, 11] and/or in the same strain grown in different 
media [13, 11]. 
Therefore, combining the above information with the consideration that we never 
observed the appearance of Bcc mutants resistant to Antarctic VOCs, we suggested 
that the antagonistic activity exhibited by the Antarctic strains was very likely due to 
the combination of different VOCs rather than to the effect of a single molecule [13, 
11]. On the other side, reported complexity in VOCs produced by Antarctic bacteria 
let quite difficult to test each identified molecule (and eventually their different 
combinations) for Bcc inhibition activity. Therefore, all our previous reports described 
the VOCs chemical diversity, not aiming at defining the association between the anti-
Bcc activity and a single volatile compound. 
One of the Antarctic bacteria tested for the ability to synthesize anti-Bcc VOCs is 
Pseudoalteromonas haloplanktis TAC125 (P. haloplanktis TAC125), which is the first 
Antarctic marine strain whose genome was sequenced and carefully annotated [14]. 
P. haloplanktis TAC125 represents a model system for the study of bacterial cold-
adaption due to: a) the availability of efficient genetic schemes for genome targeted 
insertion/deletion [15]; b) the availability of a well-settled technology for 
homologous/heterologous gene expression [16, 17]; c) the development of efficient 
schemes for bacterial cultivation in automatic fermenters, either in batch or in 
chemostat modalities [18,19]; and d) the availability of a genome-scale model of its 
metabolism [20]. Furthermore, it has also been demonstrated that this bacterium is 
able of producing an anti-biofilm compound targeting Staphylococcus epidermidis 
[21, 22].  
Since it was demonstrated that the ability of P. haloplanktis TAC125 to inhibit the 
growth of Bcc strains was influenced by the specific growth medium composition [11], 
the aim of this work was to explore the ability of this bacterium to synthesize anti-Bcc 
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VOCs when grown in different cultivation conditions and synthetic media. We 
demonstrated that when P. haloplanktis TAC125 was grown in a specific synthetic 
medium it was unable to inhibit the Bcc growth, while when grown in the same 
synthetic medium enriched by single selected amino acids, such as L-methionine, the 
bacterium was able to inhibit the growth of tested Bcc strains by VOCs production. 
Then, we set up a methodology, based on the use of an automatic fermenter, to 
produce, capture, and accumulate VOCs, which allowed us to identify the 
methylamine as one of VOCs produced by the bacterium grown in presence of L-
methionine. Finally, we evaluated methylamine antimicrobial activity against several 
Bcc strains 
 
Material and Methods: 
 
Bacterial strains and growth conditions 
P. haloplanktis TAC125 was grown at 20°C on agar-containing (15 g/L) GG medium 
(10 g/L L-glutammate, 10 g/L D-gluconate, K2HPO4 1 g/L 10 g/L NaCl, 1 g/L NH4NO3, 
200 mg/L MgSO4•7H2O, 5 mg/L FeSO4•7H2O, 5 mg/L CaCl2•2H2O pH 7.5) or 
GG+amino acid medium (final concentration of  amino acids in medium was 0.04M ). 
Bcc strains (Table 1) and Escherichia coli K12 were grown at 20°C or 37°C 
(depending on the specific assay to be carried out) on TYP medium (16 g/L yeast 
extract, 16 g/L bacto peptone, 10 g/L NaCl) containing 15 g/L agar. 
Each of the ten Bcc strain used in this work (Table 1) was grown on TYP solid 
medium or on buffered TYP at different pH values. Buffering of TYP medium was 
obtained by adding 20mM Tris buffer at different pH; in this way buffered TYP media 
with a different pH (7.0, 7.5, 8.0, 8.5, and 9.0) were obtained. 
 
Table 1. List of Bcc strains used in this work  
 
Species Strain Source 
B. arboris LMG 24066 Soil 
B. cenocepacia LMG 16654 Cystic Fibrosis Patient 
B. cenocepacia LMG 19230 Environmental 
B. contaminans LMG 23361 Animal infection 
B. latens LMG 24064 Cystic Fibrosis Patient 
B. metallica LMG 24068 Cystic Fibrosis Patient 
B. multivorans LMG 13010 Cystic Fibrosis Patient 
B. pseudomultivorans LMG 26863 Cystic Fibrosis Patient 
B. stabilis LMG 14294 Cystic Fibrosis Patient 
B. ubonensis LMG 20358 Soil 
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Cross-streaking assays 
Cross-streaking experiments were carried out as previously described [9] by using 
Petri dishes with a septum separating the two hemi-cycles, to permit the growth of 
the tester (P. haloplanktis TAC125) and target strains (Burkholderia cenocepacia 
LMG 19230 and LMG 16654 and E. coli K12) on different media without any physical 
contact. P. haloplanktis TAC125 was grown on GG agar or GG+amino acid (final 
concentration of amino acids in medium was 0.04M) agar media for 4 days at 20°C; 
then the target strains were streaked onto the TYP agar medium on the opposite 
hemi-cycle of the Petri dish with septum, and incubated at 20°C for 2 days and at 
37°C for two additional days. 
 
P. haloplanktis TAC125 cultivation in automatic fermenter 
 
The Antarctic bacterium was grown in a Sixfors HT automatic fermenter (INFORS) 
containing 1/3 TYP liquid medium (5.3 g/L yeast extract, 5.3 g/L bacto peptone, 10 
g/L NaCl), or GG medium with or without the addition of 40 mM L-methionine. The 
cultures were grown in a volume of 250 mL at 20 °C in aerobic conditions (Dissolved 
Oxygen Tension DOT≥30 %), by keeping the inlet airflow of 20 L/h and a stirring rate 
of 250 rpm. 
 
VOCs condensation system and molecules identification by Solid-phase Micro 
extraction Gas Chromatography -Mass Spectrometry (SPME-GC-MS) 
The condensation and preliminary identification experiments were carried out in 
triplicate in the following conditions: a) uninoculated GG medium; b) P. haloplanktis 
TAC125 inoculated GG medium; c) P. haloplanktis TAC125 inoculated GG-Met 
medium. Gas stream coming out from the fermentation vessel was forced to pass 
through a water trap, consisting in a bottle filled by hygroscopic salts (i.e. anhydrous 
magnesium sulfate and sodium chloride in a 1:1 w/w ratio), to eliminate as much 
water molecules as possible. Dehydrated gas was then conveyed to a distillation 
equipment located inside a cooling system (average temperature of -20°C), allowing 
the condensation of Volatile Organic Compounds eventually present in the gas 
mixture. Identification of condensed VOCs was carried out by Solid-phase Micro 
extraction Gas Chromatography - Mass Spectrometry (SPME-GC-MS), at the 
Servizio di Spettrometria di Massa at the Department of Chemical Sciences- 
Federico II University of Naples. The gas chromatographic analyses were performed 
with an Agilent 6890 Series GC, coupled to a detector MS 5973. The column used 
was a DB-5ms capillary column (30 m × 0.25mm ID, 0.25µm film, 5% phenyl 95% 
polydimethylsiloxane). Helium was used as carrier gas, with a flow of 1.0 mL/min. 
Solid-phase micro extraction was performed by using DVB/CAR/PDMS 50/30 µm 
fibre, connected to the top of the bottle containing the condensed VOCs, and the 
bottle (and its content) was heated at 230°C and exposed for 45 min in the 
headspace of the flask (adsorption). Subsequently the fibre was exposed in the 
injector of the GC, maintained at a temperature of 230°C for 3 min (desorption). The 
gradient used for analysis was as follows: 45°C for 3 min, 150°C to 12 °C/min, 230°C 
to 18°C/min, 250°C to 19°C/min. The analyzer of the GC is maintained at 250°C. The 
collision energy in the source has been set to a value of 70 eV; fragment ions 
generated were analyzed in the range of 30-450 mass m/z. 
A preliminary identification of the molecules synthesized was performed by SPME-
GC-MS. In detail, the tentative identification of the volatile components was based on 
comparison of their mass spectra with those of NIST 2.0 as well as by comparison of 
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their retention indexes with the literature data. As for methylamine, each condensed 
molecule was identified by its fragmentation mass spectrum and comparison 
between its retention time (1.58) and the retention time of a standard. 
 
Definition of Bcc strains sensitivity to methylamine and determination of 
Minimum Volatile Inhibitory Concentration (MVIC) 
Minimum Volatile Inhibitory Concentration (MVIC) is defined as the lowest 
methylamine concentration that showed no visible growth of the streaked tester strain 
after 96 hrs at 20°C. 
The gaseous methylamine was obtained through in situ acid-base reaction between 
sodium hydroxide and methylamine hydrochloride salt (SIGMA code: M0505): 
CH3NH2•HCl + NaOH excess → CH3NH2 ↑ + NaCl + H2O 
The number of moles of methylamine hydrochloride (CH3NH2•HCl), which are placed 
to react with the base solution, corresponds to the number of gaseous methylamine 
(CH3NH2↑) moles released. To define the final gaseous methylamine concentration, 
we consider the volume of the hermetically sealed incubation box (2L). For instance, 
to test on Bcc strains a final concentration of 10 mM gaseous methylamine in a 2 L 
sealed box, 1.35 g (corresponding to 20 mM) of methylamine hydrochloride salt were 
dissolved in a 1 mL of distilled water; then 200 µL of sodium hydroxide 10 M were 
added, developing 20 mM of gaseous methylamine. The boxes containing the target 
strains were incubated at 20°C for 4 days. Then the plates were recovered and 
placed at 37°C for further 2 days, to allow cells to grow on solid medium. 
 
Measurement of pH 
The pH of TYP liquid medium (1 mL volume) exposed to methylamine in the 
hermetically sealed incubation (Fig.4 (a)) was determined using Instruments XS, 
pHmeter Orto lab S.n.c.  
 
Results 
 
P. haloplanktis TAC125 is able to produce VOCs active against Burkholderia 
cepacia complex strains when grown in liquid culture 
With the aim of developing a methodology for VOCs capture from the outlet air 
stream from a bioreactor, P. haloplanktis TAC125 was grown in a multi-vessel 
automatic fermenter at 20°C in a complex rich medium (see methods section) where 
the bacterium exerts its maximal inhibitory activity against Bcc strains in conventional 
cross-streaking experiments [11]. The culture was continuously supplemented by a 
sterile air inlet (20 L/hr). The outlet gas stream during the bacterial growth was 
conveyed towards a culture bottle filled by TYP–agar medium and streaked with two 
Bcc strains (Burkholderia cenocepacia LMG 16654 and LMG 19230), which were 
inhibited by P. haloplanktis TAC125 VOCs when tested in cross-streaking 
experiments [11]. As a control, a bottle containing the same agar medium and same 
strains was subjected to the outlet gas coming from another vessel containing un-
inoculated sterile liquid medium. The outlet gases were conveyed towards culture 
bottles for at least 2 days and during this period the room temperature was fixed at 
20°C. A schematic representation of the experimental setup is shown in Fig. 1(a). 
Data obtained revealed that the growth of both Bcc strains was inhibited when 
exposed to the outlet gas from P. haloplanktis TAC125 culture (Fig. 1(b)), thus 
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demonstrating that this bacterium produces anti-Bcc VOCs even when grown in 
liquid medium. 
 
 
Fig. 1: P. haloplanktis TAC125 is able to produce VOCs when grown in liquid culture. Outlet gas 
from the P. haloplanktis TAC125 growth contains VOCs able to inhibit the growth of two Bcc strains. 
(a) Diagram describing the experimental setup; (b) Culture bottles, containing TYP-agar medium and 
streaked with the strains B. cenocepacia LMG 16654 and LMG 19230, exposed (treated) or not 
exposed (untreated) to the exhaust gas stream outlet coming out from the vessel in which the P. 
haloplanktis TAC125 is growing in exponential/stationary phase. Please, note that a hole was 
introduced in both bottles to avoid the over-pressure due to the gas stream. 
 
Development of an efficient VOCs trap for capturing the volatile compounds 
produced by P. haloplanktis TAC125  
Once established that anti-Bcc VOCs are produced when the Antarctic bacterium is 
grown in automatic fermenter, we developed a system to capture VOCs produced 
during P. haloplanktis TAC125 growth. As schematically shown in Fig. 2, the gas 
stream coming out from a P. haloplanktis TAC125 inoculated vessel was conveyed 
into a chemical water trap (for water elimination), then the gas stream was cooled at -
20°C and forced to pass into a distillation equipment, aimed at obtaining the 
condensation of all volatile molecules eventually contained. To evaluate the 
condensation efficiency of this VOCs trap, P. haloplanktis TAC125 was grown in rich 
medium at 20°C and the outlet exhaust gas were condensed. A culture bottle 
containing a streak of two Bcc target strains (LMG 19230 and LMG 16654) was 
exposed to the gas stream coming out from the VOCs trap. No growth inhibition of 
the Bcc strains was observed in this case (data not shown); confirming that the VOCs 
trap is effective in the condensation of anti-Bcc VOCs. 
 
Fig. 2: Experimental setup for the capture of VOCs produced by P. haloplanktis TAC125 when 
grown in batch in automatic fermenter. See text for a detailed description. 
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Effect of the growth medium composition on P. haloplanktis TAC125 anti-Bcc 
VOCs producing ability 
The capability of the Antarctic bacterium to inhibit the growth of Bcc strains is 
influenced by the specific growth medium composition [11], therefore we tested the 
ability of P. haloplanktis TAC125 to synthesize anti-Bcc VOCs when grown in a 
synthetic (GG) defined medium. This medium contains D-gluconate and L-glutamate 
as carbon, nitrogen and energy sources, while a salts mixture was used as mineral 
base. P. haloplanktis TAC125 growth in GG medium resulted to be well balanced, as 
calculated growth parameters (in terms of specific growth rate and biomass yield) 
resulted to be comparable to those recorded when the bacterium grows in rich 
complex media (unpublished data). 
The ability of P. haloplanktis TAC125 to inhibit the growth of two Bcc strains (B. 
cenocepacia LMG 16654 and LMG 19230) was tested by a cross-streaking 
experiment. When the Antarctic bacterium was grown on GG solid medium, it was 
unable to inhibit the growth of the Bcc target strains (Fig. S1 (a). This result paved 
the way to test the effect of the addition of several different amino acids to restore the 
P. haloplanktis TAC125 inhibition ability. To this purpose cross-streaking experiments 
were carried out using GG medium containing different amino acids and the addition 
of some of them restored the P. haloplanktis TAC125 Bcc inhibition ability (Table 2; 
Fig. S1). This finding suggested that degradation of different amino acids appeared 
to produce VOCs able to inhibit the growth of Bcc strains; however, since we have 
previously demonstrated that at least some of the anti-Bcc VOCs were sulfur-
containing compounds [10; 12], we focused our attention on GG-L-methionine 
condition (we excluded cysteine as P. haloplanktis TAC125 growth in GG+Cys liquid 
medium is very poor (data not shown)). 
Then we investigated on P. haloplanktis TAC125 growth behaviour when cultivated in 
GG medium either in the presence or in the absence of L-methionine in an automatic 
fermenter. Two batch fermentation processes were carried out at 20°C, and the 
relative growth curves are shown in Fig. 3. The addition of L-methionine to the GG 
medium resulted in a reduction of the P. haloplanktis TAC125 specific growth rate 
(from 0.24 to 0.11 h-1). However, in line with the addition of an extra carbon, nitrogen 
and eventually energy source, the final biomass produced by P. haloplanktis TAC125 
in GG-Met medium was about 15% higher than that produced in GG (Fig. 3, 
supplementary). These results strongly suggest the actual use of L-methionine as 
growth substrate for the Antarctic bacterium.  
 
Amino acid E. coli K12 B. cenocepacia 
LMG 16654 
B. cenocepacia 
LMG 19230 
L-alanine + - + 
L-asparagine  + - - 
L-aspartate  + - - 
L-cysteine + ± ± 
Glycine  + ± - 
L-serine  + - - 
L-histidine  + - - 
L-methionine  + ± - 
L-isoleucine  + + + 
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Amino acid E. coli K12 B. cenocepacia 
LMG 16654 
B. cenocepacia 
LMG 19230 
L-leucine  + ± + 
L-phenylalanine  + - - 
L-valine  + + + 
L-proline  + - - 
L-lysine  + - - 
Symbols:  + growth; ± reduced growth; - no growth. 
 
Table 2. Growth of B. cenocepacia LMG 16654 and LMG 19230 and E. coli K12 in the presence 
of P. haloplanktis TAC125 grown on GG solid medium containing different amino acids. The 
inhibition ability of the Antarctic bacterium grown on GG solid medium, supplemented with different 
amino acids, was tested by cross-streaking experiments in Petri dishes with septum, using the Bcc 
strains LMG 19230 and LMG 16654 and E. coli K12 as target strains. 
 
Identification of methylamine as a VOC produced by P. haloplanktis TAC125 
VOCs capture experiments were carried out, condensing the outlet gas from a 
culture of P.  haloplanktis TAC125 grown in GG medium or GG-Met medium, 
respectively. In both growth conditions, condensation was carried out for 48 hours, 
starting from the medium exponential growth phase and continuing over the 
stationary phase. As corresponding negative control, VOCs capture was also 
performed on the outlet gas from un-inoculated media. Condensed VOCs were kept 
at -20°C until the following identification procedure. A suitable probe for the Solid-
phase Micro extraction Gas-Chromatography - Mass Spectrometry (SPME-GC-MS) 
analysis was connected to the top of the bottle containing the condensed volatile 
molecules. The bottle (and its content) was heated to let the VOCs to interact with 
the probe. After 45 minutes exposure, the probe was connected to the mass 
spectrometer and the tentative identification analysis was carried out. Interestingly, 
when P. haloplanktis TAC125 is grown in GG medium the only volatile molecule 
identified is carbon dioxide (data not shown), thus supporting our preliminary 
observations about the absence of Bcc strain inhibition in a classical cross-streaking 
experiment (Fig. S1 (a)). The addition of L-methionine to the growth medium results 
in the production of some compounds (data not shown); one of the detected 
compounds was methylamine, whose identification was confirmed by comparison 
with a standard. Interestingly this compound has never been reported to have 
antibacterial activity, although its anti-fungi activity was previously described [23] and 
it has low toxicity towards human cells, which might allow handling this molecule 
even in uncontained laboratory conditions. 
 
Methylamine inhibits Bcc strains at different Minimal Volatile Inhibitory 
Concentrations (MVIC)  
To evaluate the antibacterial activity eventually exerted by methylamine on B. 
cenocepacia LMG 19230 and LMG 16654 strains a suitable experimental procedure 
was set up. As shown in Fig. 4(a), the target Bcc strains (and E. coli K12 as control) 
were streaked onto two TYP-agar Petri dishes, one of which was placed into a box in 
which a defined molar amount of methylamine was released by a stoichiometric 
reaction between methyl-ammonium hydrochloride and an excess of sodium 
hydroxide (see Materials and Methods for details). The box was then hermetically 
sealed and incubated at 20°C for 4 days, to allow the growth of bacteria. As positive 
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control the second Petri dish was placed in a similar hermetically sealed box, without 
the addition of methylamine, and incubated in the same conditions. Both plates were 
then recovered from the sealed boxes and further incubated at 37°C for 2 days to 
allow a better bacterial growth on solid medium, if any. 
The sensitivity of B. cenocepacia LMG 19230 and LMG 16654 strains was evaluated 
in the range of methylamine concentration between 1 and 10 mM, aiming at 
observing a dose-dependent growth inhibition and defining their Minimum Volatile 
Inhibitory Concentration (MVIC). Both strains displayed a MVIC of 10 mM, while E. 
coli K12 was able to grow when exposed to the same methylamine concentration 
(Fig. 4). Then, we applied the methylamine inhibition assay to a panel of Bcc strains, 
representative of some of the species belonging to the complex, with the aim of 
determining their respective MVIC.  
 
 
Fig. 4: Methylamine inhibition assay. Bcc strains LMG 19230, LMG 16654 and E. coli strain K12 
(control) were streaked onto two Petri dishes containing TYP-agar medium. One plate was placed into 
a box with a solution releasing a stoichiometric quantity of methylamine, the other one (positive 
control) was placed in a similar box without any gaseous addition. Bcc strains LMG 19230, LMG 
16654 and E. coli strain K12 streaked onto two Petri dishes containing TYP-agar medium exposed to 
methylamine. The plates were incubated 4 days at 20°C, then recovered from the boxes and 
incubated at 37°C for further 2 days. 
 
Data obtained are reported in Table 3. Most of the analysed Bcc strains display a 
methylamine MVIC of 20 mM, while B. latens LMG 24064 is more resistant to the 
volatile molecule, as the methylamine MVIC is above 35 mM, concentration at which 
the E. coli K12 growth is inhibited. 
A recent paper reports that several volatile compounds, in particular, trimethylamine 
(TMA), modify the antibiotic resistance proﬁles of different bacteria and that the TMA 
mode of action consists in a not speciﬁc transient alteration of antibiotic uptake due 
to pH increase in the environment of bacteria aerially exposed to the VOC [24]. In 
order to evaluate if the observed Bcc growth inhibition could be due to alkalinization 
of growth medium induced by methylamine aerial exposure, we followed the strategy 
reported in [24]. We measured the pH of 1 mL TYP liquid medium exposed to 
methylamine in the same conditions used for the MVIC test (Fig. 4(a)). Before any 
methylamine treatment, TYP liquid medium pH is 6.7± 0.1. Aerial exposure to 10 mM 
methylamine enhances TYP medium pH to 8.2±0.2, while 20 mM methylamine 
treatment increases medium final pH to 8.8±0.2. Then, we evaluated the ability of 
tested Bcc strains to grow on a modified TYP solid media buffered at different pHs (in 
the range 7.0 to 9.0) and results are shown in Table 3. With the notable exception of 
B. multivorans LMG 13010, all the Bcc strains used in this work are able to grow up 
to 8.5 and six over ten do grow at pH 9.0. Combining the information reported in 
Table 3, it is clear that the methylamine sensitivity spectrum of tested Bcc strains is 
not in agreement with their respective ability to grow at alkaline pHs. Therefore, 
although in case of B. multivorans LMG 13010 we cannot exclude the possibility that 
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the methylamine mode of action consists in a not permissive pH increase of growth 
medium, the other tested Bcc strains seem to be inhibited by methylamine regardless 
of pH variation. 
 
 
Species 
 
Strain 
 
Methylamine 
MVIC (mM) 
pH 
   7.0 7.5  8.0 8.5 9.0 
B. arboris 
LMG 
24066 
20 + + + + - 
B. cenocepacia 
LMG 
16654 
10 + + + + + 
B. cenocepacia 
LMG 
19230 
10 + + + + + 
B. contaminans 
LMG 
23361 
20 + + + + - 
B. latens 
LMG 
24064 
˃35 + + + + + 
B. metallica 
LMG 
24068 
20 + + + + - 
B. multivorans 
LMG 
13010 
20 + + ± - - 
B. 
pseudomultivorans 
LMG 
26863 
20 + + + + + 
B. stabilis 
LMG 
14294 
20 + + + + + 
B.ubonensis 
LMG 
20358 
20 + + + + + 
E. coli K12 35 + + + + + 
Symbols: + growth; ± reduced growth; - no growth. 
 
Table 3. Bcc strains Methylamine MVIC and ability to growth at different pH. For each 
Burkholderia species the list contains indication of strain number, the methylamine Minimum 
Volatile Inhibitory Concentration (MVIC) and the ability to growth on buffered TYP agar 
medium at different pH. 
 
Discussion: 
Over the last years, we have reported the ability of many marine Antarctic strains, 
including the model organism P. haloplanktis TAC125, to produce VOCs able to 
inhibit the growth of B. cepacia complex strains. This inhibition ability was 
demonstrated using the classical cross-streaking experimental conditions [9, 11], 
which implies the growth of the Antarctic strains on solid medium. In the present 
paper, we demonstrated that P. haloplanktis TAC125 has the ability to produce anti-
Bcc VOCs even when growing in liquid culture. Based on these results, we set up a 
methodology for VOCs capture, accumulation and storage by coupling the growth of 
the Antarctic bacterium in an automatic fermenter with the application of a cooling 
system to the exhaust air outlet. 
Previously reported data demonstrated that the ability of P. haloplanktis TAC125 [11] 
and other marine Antarctic bacteria [13] to inhibit the growth of Bcc strains was 
influenced by the growth medium composition. We demonstrated that when the 
Antarctic bacterium is grown on GG solid medium, it is unable to inhibit the growth of 
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the Bcc target strains. This result confirmed the tight dependence of anti-Bcc VOCs 
production on P. haloplanktis TAC125 culture medium composition, and allowed us 
to test the effect of the addition of different amino acids to restore the inhibition ability 
of the Antarctic strain. Amino acids were selected as nutrient additives as they 
represent the P. haloplanktis TAC125 preferred carbon and nitrogen sources [14]. 
Interestingly, nine amino acids are able to restore the P. haloplanktis TAC125 
antimicrobial activity when added to the GG medium (Table 2). Hence, it is possible 
that different carbon and/or nitrogen sources will activate different P. haloplanktis 
TAC125 metabolic pathways that, in turn, may end up in the production of different 
VOCs endowed with anti-Bcc activity. The different extent of growth inhibition 
displayed on the two Bcc target strains and the diverse effect of different amino acid 
addition on P. haloplanktis TAC125 inhibition ability on Bcc strains (Table 2) may be 
due to respective different sensitivity to a specific volatile compound, and/or to the 
production of different VOCs in these experimental conditions. It is indeed worth of 
mentioning that the efficiency of marine Antarctic bacteria to inhibit almost all Bcc 
strains so far tested may be related to the synergistic effect of multiple VOCs 
produced when the cells are grown in complex media. 
In this paper, we further investigated on the VOCs produced by P. haloplanktis 
TAC125 when grown in GG medium containing L-methionine. This choice relies on 
two considerations: previously reported results suggested that at least some of the 
anti-Bcc VOCs may be sulphur containing compounds [10] and L-methionine is 
known to play a pivotal role in sulphur metabolism of most organisms [24]. Moreover, 
our experiments demonstrated that P. haloplanktis TAC125 is able to grow in GG+ L-
methionine in automatic fermenter and clearly indicated that L-methionine is actually 
a growth substrate.  
The addition of L-methionine to the growth medium resulted in the production of 
some VOCs (data not shown), amongst which methylamine. This simple amine may 
be the product of several microbial metabolic reactions, and therefore we explored 
the metabolic routes used by P. haloplanktis TAC125 to produce methylamine when 
growing on GG+L-methionine medium. The genome of P. haloplanktis TAC125 was 
in silico analyzed looking for the intracellular L-methionine destiny (data not shown), 
and this analysis revealed the absence of the genes encoding some key enzymes 
involved in previously reported L-methionine degradation pathways [25,26]. The 
above considerations suggest that L-methionine catabolism of the Antarctic 
bacterium offers several aspects of novelty thus supporting the idea that P. 
haloplanktis TAC125 evolved unknown metabolic routes for the use of this amino 
acid, some of which may end up with the production of methylamine. It is interesting 
to note that almost 11% of the protein encoding genes identified in P. haloplanktis 
TAC125 genome have still no homologous in any other organism [14]. 
Even though methylamine was never identified amongst the VOCs released by the 
Antarctic bacterium when grown in complex media [14], we focused our attention on 
it, since the antimicrobial activity of this amine was never reported. Our results 
demonstrated that this molecule is able to inhibit the growth of several Bcc strains at 
different concentrations and that its mode of action does not consist in a nonspeciﬁc 
pH increase. For all tested Bcc strains methylamine MVIC resulted to be in an mM 
concentration range, making however unrealistic its use as canonical/ classical 
antibiotic agent. 
Although the identification of methylamine cellular target(s) in B. cepacia complex 
strains is out the scope of this study and will be object of future investigations, this is 
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the first paper where the anti-Bcc activity of a single volatile compound produced by 
an Antarctic marine bacterium was demonstrated. 
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SUPPLEMENTARY MATHERIAL 
 
Fig. 3: P. haloplanktis TAC125 growth curves in automatic fermenter. Comparison of P. 
haloplanktis TAC125 growth curves when the bacterium is grown at 20°C in batch in 
automatic fermenter in GG medium without (grey line) or with (black line) the addition of L-
methionine at 40 mM final concentration. Each experiment was carried out in triplicate and 
error bar represents the standard deviation of each measurements. The inset table shows 
the values of main growth parameters (µ, specific growth rate; Xmax, maximum biomass 
concentration). 
 
 
 
 
 
 
 
 
 
Fig. 1S: The inhibition ability of the Antarctic bacterium when grown on GG agar 
medium and on GG+AA. Cross-streaking experiments were carried out as previously 
described (Papaleo et al 2012) by using Petri dishes with a septum, target stains and the 
tester strain were grown on different media without any physical contact. The target strains 
(Bcc LMG 19230 and LMG 16654 and Escherichia coli K12) were grown on TYP the tester 
strain (P. haloplanktis TAC125) was grown on different media:  
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Topic II: Identification of anti-biofilm molecules against Staphilococcus 
epidermidis 
 
Biofilm is a multicellular community composed of prokaryotic and/or eukaryotic cells 
embedded in a matrix composed, at least partially, of material synthesized by the 
sessile cells in the community [45]. Biofilms were also estimated to be responsible in 
humans for a large proportion of persistent infections, such those derived from 
orthopaedic implants or indwelling catheters [46]. Indeed, pathogens embedded in 
biofilm matrix appear to be more resistant to many physical or chemical treatments, 
therefore even a well-designed antibiocidal cure often results in the selection of 
persistent pathogens cells, which are responsible for recurrent infections. However, 
issues derived from biofilm formation are not only relevant in medicine but in a wide 
range of sectors such as food industry [47], marine and industrial equipment [48]. 
Staphylococci are recognized as the most frequent causes of biofilm associated 
human infections. This exceptional status among biofilm associated pathogens is due 
to the fact that staphylococci are frequent commensal bacteria on the human skin 
and mucous surfaces. Indeed, staphylococci are among the most likely bacteria to 
infect any medical devices that penetrates those surfaces, such as when being 
inserted during surgery [49]. Staphylococcus epidermidis (S. epidermidis) contributes 
to making infections chronic and particularly difficult to eradicate. 
The interest in the development of new approaches for the prevention and treatment 
of adhesion and biofilm formation capabilities has increased. A viable approach 
should target adhesive properties without affecting bacterial vitality in order to avoid 
the rapid appearance of escape mutants. Molecules implicated in active biofilm 
dispersal include glycosidases and proteases. There is a notable effort towards 
finding small available molecules that should “break up” the “tangled matrix” of the 
biofilm.  
Previous results [24] show that the cell-free supernatant of P. haloplanktis TAC125 
grown in static condition strongly inhibited the biofilm of S. epidermidis.  
In particular, in the second part of my Ph.D. thesis you will find three papers: 
 The first paper reports the definition of the best experimental condition in 
which P. haloplanktis TAC125 produces the anti-biofilm molecule. In 
particular, several process parameters were evaluated such as mode of 
bacterial growth, temperature and composition of medium. As often observed 
in many other bacterial biofilms, also P. haloplanktis TAC125 biofilm kinetic is 
characterized by an alternation of attachment and detachment phases. In 
order to assess the biofilm kinetic, the production of biofilm was evaluated 
daily (in the range 1-5 days). The supernatant of each condition was 
recovered and its effect on S.epidermidis strain O-47 was analyzed.  
A purification procedure was set up and the analysis of an enriched fraction 
demonstrated that the anti-biofilm activity is not due to a polysaccharide 
molecule but that it is due to small hydrophobic molecules that likely work as 
signal. 
 In the second paper the set-up of biofilm cultivation of P. haloplanktis TAC125 
in automatic bioreactor was proposed. The development of an efficient biofilm 
cultivation scheme in automatic fermenter is necessary to obtain a large 
amount of cell-free supernatant necessary for the anti-biofilm molecule/s 
purification; and the recovery of P. haloplanktis TAC125 cells grown in biofilm 
for physiologic studies. A fluidized-bed reactor fermentation in which selected 
floating polystyrene supports were homogeneously mixed and properly 
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exposed at the air-liquid interface was set up. The production of the anti-
biofilm molecules from P.haloplanktis TAC125 in this condition was evaluated. 
This strategy allowed a larger-scale production of anti-biofilm molecule/s and 
paved the way to study of differences between P. haloplanktis TAC125 cells 
grown in biofilm and in planktonic conditions. In particular, the modiﬁcations 
occurring in the lipopolysaccharide of cells grown in biofilm were investigated. 
 In the third paper the anti-biofilm activity of supernatants derived from cultures 
of cold-adapted bacteria belonging to Pseudoalteromonas, Psychrobacter, 
and Psychromonas genera was evaluated. In particular, supernatants were 
obtained from bacterial cultures made both in sessile and planktonic 
conditions. The potential anti-biofilm activity was tested on bacterial cultures of 
P. aeruginosa PAO1, three different strains of S. aureus and three different 
strains belonging S. epidermidis species. A preliminary physico-chemical 
characterization of supernatants was also performed, and these analyses 
highlighted the presence of molecules of different nature that act by inhibiting 
biofilm formation. Some of them are also able to impair the initial attachment of 
the bacterial cells to the surface, thus likely containing molecules acting as 
anti-biofilm surfactant molecules. 
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Cryoprotectants 
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Topic III: Study of “cryoprotectant” molecules for biotechnological application 
 
The application of cryopreservation to living cells and tissues has revolutionized 
many Biotechnology areas, such as plant and animal breeding programs, and 
modern medicine.  
Freeze-thaw cycles are quite common in the cold Polar Regions. Cold-adapted 
microorganisms are accustomed to being frozen within their habitats. Such 
organisms are also expected to have evolved adaptations to survive repeated 
freezing and thawing cycles, as these processes tend to damage living cells and 
attenuate cell viability. Cold-adapted bacterium Colwellia psychrerythraea strain 34H 
(C psychrerythraea 34H), whose genome was sequenced [38], has attracted 
particular attention because it was reported to produce cryoprotectants [50] as a 
survival strategy [40]. In particular, C psychrerythraea 34H cells are surrounded by a 
polysaccharidic capsule. Amongst all molecules to show cryoprotectant activity, the 
importance of sugars as CPA was clearly recognized by Maximov in the early 1900’s 
[51]. 
In this part of my thesis the chemical analysis of purified capsular material from C 
psychrerythraea 34H cells revealed the occurrence of a novel structure amongst 
bacterial polysaccharides: a linear tetrasaccharide repeating unit containing two 
amino sugars and two uronic acid, of which one is amidated by a threonine. The 
presence of amminoacid is quite uncommon in marine bacteria. The decoration of 
the polysaccharide with Thr is particularly intriguing, as glycosilated Thr residues are 
essential for the interaction of anti-freeze glycoproteins (AFGPs) with ice crystals 
[52]. In line with this indirect observation, in vitro assays demonstrated that the C. 
psychrerythraea 34H capsular polysaccharide is endowed with ice re-crystallization 
inhibition activity.  
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CONCLUSIONS 
 
Cold marine regions have been underexplored, and indigenous microbiota may be 
endowed of a more interesting chemical repertoire. The microorganisms that thrive in 
these cold environments are referred to as psychrophiles or cold-adapted. A 
preliminary characterization of molecules isolated from these bacteria suggested that 
these compounds may found applications in many biotechnological fields. 
In my PhD project I worked on three chemical classes of bioactive compound from 
marine microorganisms: antimicrobial Volatile Organic Compounds (VOCs), anti-
biofilms molecules, and cryoprotectants. 
I demonstrated that Pseudoalteromonas haloplanktis TAC125 is able to produce 
volatile bioactive molecules endowed with an inhibitory activity against human 
pathogens belonging to the Burkholderia cepacia complex (Bcc). Moreover one of 
these molecules, methylamine, was identified and I demonstrated that this molecule 
is able to inhibit the growth of several Bcc strains in dose-dependent way. 
My work also proved that Pseudoalteromonas haloplanktis TAC125 is able to 
produce anti-biofilm molecule/s against the biofilm of one of the major human 
opportunistic pathogens, Staphilococcus epidermidis. Moreover, I demonstrated that 
cold-adapted bacteria belonging to Pseudoalteromonas, Psychrobacter, and 
Psychromonas genera are able to produce anti-biofilm compounds active against 
opportunistic pathogens such as Staphilococcus aureus and Pseudomonas 
aeruginosa. 
As for cryoprotectant molecules, my attention was focused on the cold adapted 
bacterium Colwellia psychrerythraea 34H. 
Colwellia psychrerythraea 34H resulted to have a capsula with a very peculiar 
structure. The particularity of this molecules is the presence of a threonine on a linear 
tetrasaccharide repeating unit, likely the presence of threonine is responsible of 
cryoprotectant activity of capsular material.  
 
In conclusion, my PhD work clearly demonstrated that cold adapted bacteria are very 
promising source of biotechnologically relevant molecules.  
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